

ANAPHYLAXIS UK

England & Wales · Charity number 1085527

Details

Other names	ANAPHYLAXIS CAMPAIGN (INCORPORATING THE LATEX ALLERGY SUPPORT GROUP), THE ANAPHYLAXIS CAMPAIGN, ANAPHYLAXIS CAMPAIGN
Status	Registered
Legal form	Charitable company
Company number	04133242
Registered	2001-03-13
Register	View on the Charity Commission register

Contact

Address	96A Frimley High Street Frimley Surrey GU16 7JE
Phone	01252 546100
Email	admin@anaphylaxis.org.uk
Website	www.anaphylaxis.org.uk

Activities

Objects: TO ADVANCE THE EDUCATION AND GENERAL UNDERSTANDING OF THE PUBLIC CONCERNING LIFE THREATENING ALLERGIES AND ASSOCIATED DISORDERS.TO PROTECT THE HEALTH OF PEOPLE WHO MAY BE AT RISK OF SEVERE ALLERGIC REACTIONS BY PROVIDING HELP AND INFORMATION TO THEM, THEIR FAMILIES AND FRIENDS.TO PROMOTE RESEARCH INTO THE CAUSE AND CARE OF SEVERE ALLERGIC CONDITIONS AND TO PUBLISH THE RESULTS OF SUCH RESEARCH.

Activities: To advance the education and general understanding of the public concerning life-threatening allergies and associated disorders. To protect the health of people who suffer severe allergic reactions by providing help and information to them, their families and friends and to promote research into the cause and care of severe allergic conditions and to publish the results of such research.

Classification

- **How:** Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** People With Disabilities

Geography

- **Area of benefit:** NOT DEFINED. IN PRACTICE NATIONAL.
- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£633,652	£565,698	£708,565	9
2023-12-31	£586,097	£579,487	£629,729	8
2022-12-31	£540,894	£529,537	£613,648	8
2021-12-31	£522,822	£480,038	£610,369	12
2020-12-31	£622,281	£495,062	£560,834	13

Trustees

Name	Role	Appointed
Caroline Claire Ann Fearnley		2023-07-17
David Richard Webster		2026-01-01
Dr Alison Walker-Fraser		2017-12-12
Dr Helen Eve Evans-Howells		2021-11-01
James John Daley		2024-06-07
Louise Claire Wilkinson		2020-12-01
Peter Michael Littleton		2020-12-01
Richard James Wright		2021-11-12
Tajinder Randhawa		2020-12-01

ANAPHYLAXIS UK

England & Wales - Charity number 1085527

Accounts

REGISTERED COMPANY NUMBER: 04133242 (England and Wales)
REGISTERED CHARITY NUMBER: 1085527

REPORT OF THE TRUSTEES AND
UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024
FOR
ANAPHYLAXIS UK

Rock Tax & Accounting
Elm House, Tanshire Park
Shackleford Road
Elstead
Godalming
Surrey
GU8 6LB

ANAPHYLAXIS UK

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Page
Report of the Trustees	1 to 8
Independent Examiner's Report	9
Statement of Financial Activities	10
Balance Sheet	11 to 12
Cash Flow Statement	13
Notes to the Cash Flow Statement	14
Notes to the Financial Statements	15 to 23
Detailed Statement of Financial Activities	24 to 25

ANAPHYLAXIS UK**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024**

2024 - Expanding Reach, Deepening Impact

2024 was a year of remarkable progress for Anaphylaxis UK. Building on strong foundations, we reached more people than ever before with trusted support, practical tools and powerful awareness campaigns. Our work extended across communities, schools, workplaces, healthcare settings and international forums - always with the same goal: to improve the quality of life for everyone living with a serious allergy.

Through new partnerships, innovative resources and a growing digital presence, we deepened our impact while keeping lived experience at the heart of what we do. From the helpline to the boardroom, from classrooms to global conferences, 2024 was a year of action, connection and change.

Patient and Public Information & Support

In 2024, our helpline continued to be a trusted lifeline, responding to over 1,500 allergy-related queries by phone and email. Every call and email was handled with empathy, professionalism and practical advice, ensuring that patients, carers and families received timely support tailored to their needs.

Our library of factsheets, all accredited with the Patient Information Forum's PIF TICK quality mark, provided reliable, evidence-based information that was accessed more than 375,000 times this year. This recognition not only affirms our commitment to quality but also reflects the continued trust placed in our resources.

To reach audiences in new ways, we launched Let's Talk About Allergies in August - a podcast series featuring leading experts in the field. The first eight episodes, downloaded over 1,600 times, gave listeners the chance to hear directly from specialists on managing allergies and improving quality of life.

We also produced eight new patient posters focusing on practical allergy management and mental wellbeing, giving people accessible tools to manage daily life. Our new 20-member lived-experience advisory group began guiding resource creation, ensuring that our outputs remain firmly rooted in patient realities.

Regular weekly news articles covered emerging research, management tips and calls for involvement in studies - keeping our community informed and connected.

A notable highlight was our collaboration with University Hospitals Plymouth NHS Trust to produce a multimedia bee and wasp venom allergy awareness campaign, including podcasts, a mini-guide, a patient flowchart and educational posters.

Key achievements in 2024 :

- 1,500+ helpline enquiries supported
- 375,000+ factsheet views
- 8 podcast episodes released, 1,600+ downloads
- 8 new patient posters developed
- Established a 20-member lived-experience advisory group
- Weekly allergy news articles published
- Bee and wasp venom awareness campaign launched in partnership with NHS Plymouth

ANAPHYLAXIS UK**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024**

Research & Evidence Development

We strengthened our research partnerships to advance the evidence base in allergy prevention, management and emotional support.

With the University of Southampton and Professor Graham Roberts, we continued a five-year study aimed at preventing infant food allergies, attending fortnightly project management meetings to ensure patient perspectives remained central.

Our collaboration with the University of Birmingham's FAIR study addressed inequalities in allergy management among South Asian adults, shaping surveys and targeted communication.

The University of Surrey partnership explored the psychological impact of severe allergic reactions, particularly bereavement and near-fatal anaphylaxis. This work lays the foundation for new national guidance on emotional and psychological support.

Internationally, we co-authored European consensus statements on managing allergies in schools and contributed to a global set of ten practical priorities for allergy care. Our participation in the Food Allergy in Children Priority Setting Partnership (James Lind Alliance & University of Bristol) ensured that patient needs influenced the research agenda.

Key achievements in 2024:

- Continued multi-year infant allergy prevention study with Southampton University
- FAIR study partnership addressing healthcare inequalities
- Service evaluation on psychological support needs with University of Surrey
- Co-authored European consensus statements on school allergy management
- Contributed to a global set of ten allergy care priorities
- Member of the Food Allergy in Children Priority Setting Partnership

Professional Engagement & Collaboration

Our engagement with healthcare and industry professionals deepened in 2024, helping to raise standards in allergy management across multiple sectors.

Our monthly newsletter for healthcare professionals, achieving an exceptional open rate of over 60%. At the BSACI Annual Conference, our Speaker's Corner presentations showcased the impact of AllergyWise training and audits, while our participation in the GA²FA Forum in Padua facilitated dialogue with international leaders in allergy care.

We also contributed patient insight to steering groups such as the BRIT Registry, BSACI EEDI, CYANS (Children and Young People's Allergy Network Scotland) and the Allergy in the Military group. In the food industry, we delivered allergen control training to teams at Nestlé York, bringing the human impact of allergies into focus for decision-makers.

Key achievements in 2024:

- Monthly healthcare newsletter launched, 60%+ open rate
 - Presentations at BSACI Annual Conference and GA²FA Forum
 - Participation in national and international steering groups
 - Industry training day with Nestlé York on allergen control
-

ANAPHYLAXIS UK**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024**

AllergyWise Training

AllergyWise underwent a major transformation in 2024. We introduced face-to-face training in September, visiting 21 schools, nurseries and businesses. The impact has been remarkable: 98% of attendees felt more confident in managing allergies and the same proportion reported increased confidence in using adrenaline auto-injectors.

We also redesigned the education section of our website for easier navigation and implemented automated invoicing, reducing administrative load and improving the user experience. Our e-learning courses continued to be highly valued, with 96% of school-based participants reporting improved knowledge of anaphylaxis management.

Partnerships with organisations such as SAPHNA, the National College, Twinkl and RLSS expanded our reach. The National College course alone has received 4,000+ five-star reviews.

We also collaborated with the Department for Education Early Years team to review sector resources and delivered webinars for local authorities, cementing our reputation as a trusted training provider.

Key achievements in 2024:

- Face-to-face AllergyWise training launched, 21 sites visited
- 98% of attendees more confident in managing allergies and using AAI's
- Education website restructure and automated invoicing
- 96% of e-learning users improved anaphylaxis knowledge
- Partnerships with SAPHNA, Twinkl, National College, RLSS and more
- 4,000+ five-star reviews for National College course

Communications and Campaigns

Our communications work in 2024 reached more people than ever. Website visits rose 11% to over 600,000, with total page views reaching 1.34 million. Our monthly Allergy Outlook newsletter subscriber base grew by 102% to more than 25,000, while our new Education Newsletter reached over 2,000 subscribers in its first months, with a 72% open rate.

On social media, we built a stronger and more engaged community, growing our Facebook following to 21,600, Instagram to over 9,000 and LinkedIn to over 2,200. Overall engagements across channels rose by 76%, totalling 125,000 for the year.

Our campaigns included:

- **Vegan Food Labelling Awareness** with the Food Standards Agency
- **Bee & Wasp Venom Awareness** with ALK - our 3rd most visited page of 2024
- **Anaphylaxis Awareness Week** with the launch of Hidden Battle with Allergies, highlighting the emotional impact of allergy

Key achievements in 2024:

- 600,000+ website visitors; 1.34 million page views
 - Newsletter subscribers up 102% to 25,000+
 - 76% increase in social media engagement
 - Successful national campaigns on vegan labelling, bee & wasp venom and emotional impact of allergies
-

ANAPHYLAXIS UK**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024**

Fundraising Highlights

Fundraising in 2024 was both creative and record-breaking. Our London Marathon team raised £40,631 - the highest amount in our history. The Big Give's Christmas Challenge brought in £17,300 for Hidden Battle with Allergies, supported by corporate partners such as Fullers, Serve Legal, Boss Digital and Kitt Medical.

Our 30th anniversary "30 for 30" challenge inspired community fundraising, from school events to personal feats, raising nearly £2,000. We also received £5,000 from major donors and £30,718 through in-memoriam donations - a testament to the deep personal connection people have with our mission.

Key achievements in 2024:

- Record-breaking £40,631 from London Marathon team
- £17,300 raised via Big Give Christmas Challenge
- Nearly £2,000 from "30 for 30" community fundraising events
- £30,718 in in-memoriam donations
- £5,000 from major donors

Investment performance achieved against investment objectives

The investment objectives of the Charity are to maximise the value of reserves, while avoiding undue risk. The Charity's policy on investment includes a requirement to limit investments to 60% of liquid assets and only to invest in Funds regulated by the Financial Conduct Authority. The Charity's investments in an Income and Growth portfolio with Hargreaves Lansdown showed a gain of £10,882 on the value report at the end of December 2023 (£164,295). The value at the end of December 2024 was £175,177.

Financial review: Reserves policy

To achieve a sound balance between prudence and ensuring funds are expended in achieving the objectives of the Charity, the Trustees have established a policy whereby the unrestricted reserves held by the Charity should equate to at least six months operating costs. At the year end this equated to £343,181. Free reserves (excluding 6 months operating costs) at 31 December 2024 stood at £383,396.

Restricted reserves

Details of restricted funds are shown in note 18 of the financial statements.

Risk review

The Trustees have conducted a review of the major risks to which the Charity is exposed and systems have been established to manage those risks. A risk management register is maintained and risks highlighted are reviewed regularly to ensure they do not pose a threat to the Charity going forward. Key risks for the Charity include an uncertain economic outlook and its impact on fundraising by individuals and financial support from businesses.

ANAPHYLAXIS UK**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024**

Financial overview

The Charity ended the year in a sound financial position with sufficient free reserves to meet its reserves policy. Net outgoing resources for the year amounted to £565,698. Unrestricted funds were £706,427 and restricted funds were £2,138.

Financial policies

All payments up to £10,000 made by the Charity have to be signed by two authorised signatories and by a Trustee in addition for payments over that amount. The day-to-day management of the financial affairs of the Charity is delegated to the Head of Finance and Operations who submits Management Accounts and a written report monthly to the CEO and Board of Trustees. A financial report supported by Management Accounts is delivered by the Head of Finance and Operations at each meeting of the Trustees.

Principal funding sources

The principal funding sources for the charity are community fundraising initiatives such as the London Marathon, sales from our AllergyWise training programme and from Business Membership. The charity also benefits from grants and sponsorship of project work such as awareness campaigns.

Use of funds

Funds received by the charity have contributed significantly to the expansion of services offered by the Information Team and in our ability to enhance our awareness campaigns to reach more people with allergies.

Plans for the Future

The Board have agreed a Strategic Framework for 2024-2028. The general impact the Anaphylaxis UK charity aims to achieve by the end of 2028 is:

We want everyone with a serious allergy to enjoy the same quality of life as someone without an allergy. Over the next five years, all of our work will focus on making this ambition a reality.

Our main priority areas and the impact we aim to achieve within each area are set out in the Business Plan since they were approved by the Board in March 2024. The main areas for future work are:

At Anaphylaxis UK, our mission remains clear and urgent: to be the leading source of trusted support, information and advocacy for people living with serious allergies. In 2024, we took significant steps forward in realising that mission - broadening our reach, deepening our impact and strengthening our voice in a world where confusion, outdated beliefs and lack of awareness about allergies still create barriers to understanding.

We know that the effects of living with a serious allergy extend well beyond the individual. Families, friends, schools, workplaces and communities all feel the impact. That is why we remain committed to delivering support that is both practical and compassionate - whether through our expanding helpline, our suite of factsheets and digital resources, or our growing network of peer support groups. In 2024, over 375,000 people accessed our information library, our helpline supported more than 1,500 individuals and our new "Let's Talk About Allergies" podcast extended our reach even further.

We continued to invest in resources that reflect the real-world challenges people face- developing posters on mental wellbeing, launching emotional support initiatives following research into bereavement and trauma and bringing lived experience into the heart of our resource development through a new advisory group.

ANAPHYLAXIS UK**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024**

This year, we also strengthened our work with professionals and businesses. Our partnerships ranged from co-authoring international consensus papers on allergy management in schools, to delivering allergy education at corporate training days with food industry leaders. We are committed to working with businesses large and small - supporting them to improve their ways of working, understand the human impact of serious allergies and implement changes that make a meaningful difference to the quality of life of their customers and employees.

Raising public awareness and addressing misunderstandings about allergy remain central to our work. Our campaigns - such as the Bee and Wasp Venom Awareness programme, the FSA-led vegan food labelling initiative and the launch of our Hidden Battle with Allergies project - have helped shine a light on issues that often go unseen. The latter highlighted the emotional toll of allergy and sparked a national conversation that we will continue to champion into 2025.

We have also significantly grown our digital presence: our website saw more than 600,000 visitors in 2024 and our newsletter subscriber base doubled to over 25,000. Social media engagement grew by over 76%, reflecting a wider community that is active, engaged and hungry for credible, practical information.

None of this would be possible without the dedicated support of our staff, whose professionalism and passion drive everything we do. Nor could we achieve this without the generosity of our donors, fundraisers, partners and volunteers. Whether through time, money, or shared expertise - your support ensures that we can continue to be a lifeline for people living with serious allergies.

Looking ahead, we will build on this foundation. We aim to grow our support networks, expand our work with businesses and ensure that people know where to turn when they need clear, reliable information and practical help. Above all, we will stay focused on improving quality of life - supporting people to manage their allergies with greater confidence and less fear.

Thank you for standing with us.

Statement of Trustees' responsibilities

The trustees (who are also directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
 - the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.
-

ANAPHYLAXIS UK

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024**

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent Examiners

Rock Tax & Accounting were appointed Independent Examiners at the Annual General Meeting of the Charity held on 29 August 2025.

Structure, governance and management

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

Reference and administrative details

Registered Company number

04133242 (England and Wales)

Registered Charity number

1085527

Registered office

96a High Street
Frimley
Surrey
GU16 7JE

Trustees

Dr A M Walker-Fraser Chair
Mr P M Littleton Vice Chair
Mrs T Randhawa
Mrs L C Wilkinson
Mrs S C Hall (resigned 10.4.24)
Dr H E Evans-Howells
Mr R J Wright KC
Ms C C A Fearnley
Mr J J Daley (appointed 7.6.24)

Company Secretary

Mrs L A Ingram

Independent Examiner

Chris Lowry FCA
Rock Tax & Accounting
Elm House, Tanshire Park
Shackleford Road
Elstead
Godalming
Surrey
GU8 6LB

Approved by order of the board of trustees on and signed on its behalf by:

ANAPHYLAXIS UK

**REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 31 DECEMBER 2024**

Signed by:

Alison Walker-Fraser

09 September 2025

1G4B1F0D180E469:.....
Dr A M Walker-Fraser - Trustee

**INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF
ANAPHYLAXIS UK**

Independent examiner's report to the trustees of Anaphylaxis UK ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2024.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement


Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed by:



1CB9094F8AEB40A...

Chris Lowry FCA

The Institute of Chartered Accountants in England and Wales

Rock Tax & Accounting
Elm House, Tanshire Park
Shackleford Road
Elstead
Godalming
Surrey
GU8 6LB

09 September 2025

Date:

ANAPHYLAXIS UK

STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2024

	Notes	Unrestricted fund £	Restricted funds £	31.12.24 Total funds £	31.12.23 Total funds £
Income and endowments from					
Donations and legacies	2	542,265	2,138	544,403	551,512
Other trading activities	3	78,492	-	78,492	31,202
Investment income	4	10,757	-	10,757	3,383
Total		<u>631,514</u>	<u>2,138</u>	<u>633,652</u>	<u>586,097</u>
Expenditure on					
Raising funds	5	173,793	-	173,793	79,256
Charitable activities					
Charitable activities	6	391,691	-	391,691	496,285
Other		214	-	214	3,946
Total		<u>565,698</u>	<u>-</u>	<u>565,698</u>	<u>579,487</u>
Net gains on investments		<u>10,882</u>	<u>-</u>	<u>10,882</u>	<u>9,471</u>
NET INCOME		76,698	2,138	78,836	16,081
Reconciliation of funds					
Total funds brought forward		629,729	-	629,729	613,648
Total funds carried forward		<u><u>706,427</u></u>	<u><u>2,138</u></u>	<u><u>708,565</u></u>	<u><u>629,729</u></u>

The notes form part of these financial statements

ANAPHYLAXIS UK

BALANCE SHEET
31 DECEMBER 2024

	Notes	Unrestricted fund £	Restricted funds £	31.12.24 Total funds £	31.12.23 Total funds £
Fixed assets					
Intangible assets	12	39,330	-	39,330	37,963
Tangible assets	13	5,576	-	5,576	10,933
Investments	14	175,178	-	175,178	164,296
		<u>220,084</u>	<u>-</u>	<u>220,084</u>	<u>213,192</u>
Current assets					
Stocks	15	-	-	-	311
Debtors	16	201,574	-	201,574	150,045
Cash in hand		351,725	2,138	353,863	322,519
		<u>553,299</u>	<u>2,138</u>	<u>555,437</u>	<u>472,875</u>
Creditors					
Amounts falling due within one year	17	(66,956)	-	(66,956)	(56,338)
		<u>486,343</u>	<u>2,138</u>	<u>488,481</u>	<u>416,537</u>
Net current assets					
		<u>486,343</u>	<u>2,138</u>	<u>488,481</u>	<u>416,537</u>
Total assets less current liabilities					
		<u>706,427</u>	<u>2,138</u>	<u>708,565</u>	<u>629,729</u>
NET ASSETS					
		<u>706,427</u>	<u>2,138</u>	<u>708,565</u>	<u>629,729</u>
Funds					
	18			706,427	629,729
Unrestricted funds				706,427	629,729
Restricted funds				2,138	-
Total funds					
				<u>708,565</u>	<u>629,729</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

The notes form part of these financial statements

ANAPHYLAXIS UK

BALANCE SHEET - continued
31 DECEMBER 2024

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on09 September 2025..... and were signed on its behalf by:

Signed by:



104B1F0D100E469:.....

Dr A M Walker-Fraser - Trustee

The notes form part of these financial statements

ANAPHYLAXIS UK

**CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Notes	31.12.24 £	31.12.23 £
Cash flows from operating activities			
Cash generated from operations	1	38,839	(37,824)
Net cash provided by/(used in) operating activities		<u>38,839</u>	<u>(37,824)</u>
Cash flows from investing activities			
Purchase of intangible fixed assets		(18,076)	(12,632)
Purchase of tangible fixed assets		(350)	(3,448)
Purchase of fixed asset investments		-	(1)
Sale of intangible fixed assets		-	2,950
Sale of tangible fixed assets		174	(2,950)
Interest received		10,757	3,383
Net cash used in investing activities		<u>(7,495)</u>	<u>(12,698)</u>
Change in cash and cash equivalents in the reporting period			
		31,344	(50,522)
Cash and cash equivalents at the beginning of the reporting period			
		<u>322,519</u>	<u>373,041</u>
Cash and cash equivalents at the end of the reporting period			
		<u><u>353,863</u></u>	<u><u>322,519</u></u>

The notes form part of these financial statements

ANAPHYLAXIS UK

**NOTES TO THE CASH FLOW STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024**

1. Reconciliation of net income to net cash flow from operating activities	31.12.24	31.12.23	
	£	£	
Net income for the reporting period (as per the Statement of Financial Activities)	78,836	16,081	
Adjustments for:			
Depreciation charges	22,027	21,456	
Gain on investments	(10,882)	(9,471)	
Loss on disposal of fixed assets	214	3,946	
Interest received	(10,757)	(3,383)	
Decrease in stocks	311	517	
Increase in debtors	(51,528)	(79,357)	
Increase in creditors	10,618	12,387	
Net cash provided by/(used in) operations	<u>38,839</u>	<u>(37,824)</u>	
2. Analysis of changes in net funds			
	At 1.1.24	Cash flow	At 31.12.24
	£	£	£
Net cash			
Cash at bank and in hand	322,519	31,344	353,863
	<u>322,519</u>	<u>31,344</u>	<u>353,863</u>
Total	<u>322,519</u>	<u>31,344</u>	<u>353,863</u>

The notes form part of these financial statements

ANAPHYLAXIS UK

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024**

1. Accounting policies
Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

Preparation of consolidated financial statements

The financial statements contain information about Anaphylaxis UK as an individual company and do not contain consolidated financial information as the parent of a group. The charity is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Anaphylaxis UK has one subsidiary, Anaphylaxis UK Trading Ltd. The registered office of the subsidiary is 96a High Street, Frimley, Surrey GU16 7JE. Anaphylaxis UK owns 100% of the £1 ordinary share capital of the subsidiary.

The subsidiary company carries out trading activities related to the objectives of Anaphylaxis UK. All the taxable profits of the subsidiary are paid by gift to Anaphylaxis UK and are used in the furtherance of the charity's objectives. Consequently, the total reserves of the subsidiary are its £1 ordinary share capital.

Total income and expenditure of the subsidiary in the year to 31 December 2024 were £265,313 (£2023 - £264,800), including £183,240 (2023 - £258,889) paid by gift to Anaphylaxis UK.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery - 25% on cost

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

ANAPHYLAXIS UK

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

1. Accounting policies - continued

Fund accounting

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease.

Investments

Fixed asset investments are treated as a single asset, revalued each year to current market value.

2. Donations and legacies

	31.12.24	31.12.23
	£	£
Donations - members	25,304	27,638
Memoriam donations	30,718	19,828
Gift aid	37,599	27,636
Community fundraising & events	43,954	46,233
Charitable trusts and major donors	62,300	20,600
Corporate donations	11,862	7,135
Legacies	-	501
Individual membership	41,715	43,876
Professional membership	155	2,443
Other including Google Adwords	107,556	96,733
Income from subsidiary	183,240	258,889
	<u>544,403</u>	<u>551,512</u>

Since 1 January 2023 a number of activities previously undertaken by Anaphylaxis UK have been carried out by its subsidiary, Anaphylaxis UK Trading Ltd. These include corporate membership, Allergywise training, product recall work, events, special projects and some other activities. All of Anaphylaxis UK Trading Ltd's surplus for the year is gifted to Anaphylaxis UK and is included in Donations and Legacies.

3. Other trading activities

	31.12.24	31.12.23
	£	£
Event income	40,631	15,322
Special project income	37,500	12,380
Other sundry income	361	-
Corporate sponsorship	-	3,500
	<u>78,492</u>	<u>31,202</u>

ANAPHYLAXIS UK

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

4. Investment income		31.12.24	31.12.23
		£	£
Dividends and interest rec'd		10,757	3,383
		<u> </u>	<u> </u>
5. Raising funds			
Raising donations and legacies		31.12.24	31.12.23
		£	£
Staff costs		95,753	26,269
Other fundraising costs		7,311	10,650
Support costs		70,729	42,337
		<u> </u>	<u> </u>
		173,793	79,256
		<u> </u>	<u> </u>
6. Charitable activities costs			
	Direct	Support	
	Costs	costs (see	Totals
	£	£	£
Charitable activities	260,224	131,467	391,691
	<u> </u>	<u> </u>	<u> </u>
7. Support costs			
	General	Governance	
	costs	costs	Totals
	£	£	£
Raising donations and legacies	42,604	28,125	70,729
Charitable activities	126,667	4,800	131,467
	<u> </u>	<u> </u>	<u> </u>
	169,271	32,925	202,196
	<u> </u>	<u> </u>	<u> </u>
8. Net income/(expenditure)			
Net income/(expenditure) is stated after charging/(crediting):			
		31.12.24	31.12.23
		£	£
Depreciation - owned assets		5,319	6,554
Hire of plant and machinery		3,600	7,705
Other operating leases		48,415	45,246
Deficit on disposal of fixed assets		214	3,946
Computer software amortisation		16,709	14,902
		<u> </u>	<u> </u>

ANAPHYLAXIS UK

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

9. Trustees' remuneration and benefits

There were no trustees' remuneration or other benefits for the year ended 31 December 2024 nor for the year ended 31 December 2023.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 December 2024 nor for the year ended 31 December 2023.

10. Staff costs

	31.12.24	31.12.23
	£	£
Wages and salaries	313,432	305,647
	<u>313,432</u>	<u>305,647</u>

The average monthly number of employees during the year was as follows:

	31.12.24	31.12.23
Fundraising	2	1
Charitable activities	7	7
	<u>9</u>	<u>8</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	31.12.24	31.12.23
£60,001 - £70,000	1	-
£70,001 - £80,000	1	1
	<u>2</u>	<u>1</u>

11. Comparatives for the statement of financial activities

	Unrestricted fund £	Restricted funds £	Total funds £
Income and endowments from			
Donations and legacies	551,512	-	551,512
Other trading activities	31,202	-	31,202
Investment income	3,383	-	3,383
Total	<u>586,097</u>	<u>-</u>	<u>586,097</u>
Expenditure on			
Raising funds	79,256	-	79,256
Charitable activities			
Charitable activities	496,285	-	496,285
Other	3,946	-	3,946

ANAPHYLAXIS UK

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

11. Comparatives for the statement of financial activities - continued

	Unrestricted fund £	Restricted funds £	Total funds £
Total	579,487	-	579,487
Net gains on investments	9,471	-	9,471
NET INCOME	16,081	-	16,081
Reconciliation of funds			
Total funds brought forward	613,648	-	613,648
Total funds carried forward	<u>629,729</u>	<u>-</u>	<u>629,729</u>

12. Intangible fixed assets

	Computer software £
Cost	
At 1 January 2024	58,302
Additions	18,076
At 31 December 2024	<u>76,378</u>
Amortisation	
At 1 January 2024	20,339
Charge for year	16,709
At 31 December 2024	<u>37,048</u>
Net book value	
At 31 December 2024	<u>39,330</u>
At 31 December 2023	<u>37,963</u>

ANAPHYLAXIS UK

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024
13. Tangible fixed assets

	Plant and machinery £
Cost	
At 1 January 2024	25,889
Additions	350
Disposals	(3,115)
At 31 December 2024	<u>23,124</u>
Depreciation	
At 1 January 2024	14,956
Charge for year	5,319
Eliminated on disposal	(2,727)
At 31 December 2024	<u>17,548</u>
Net book value	
At 31 December 2024	<u>5,576</u>
At 31 December 2023	<u>10,933</u>

14. Fixed asset investments

	Shares in group undertakings £	Listed investments £	Totals £
Market value			
At 1 January 2024	1	164,295	164,296
Revaluations	-	10,882	10,882
At 31 December 2024	<u>1</u>	<u>175,177</u>	<u>175,178</u>
Net book value			
At 31 December 2024	<u>1</u>	<u>175,177</u>	<u>175,178</u>
At 31 December 2023	<u>1</u>	<u>164,295</u>	<u>164,296</u>

There were no investment assets outside the UK.

Anaphylaxis UK holds the entire £1 share capital of its trading subsidiary Anaphylaxis UK Trading Ltd. The subsidiary began trading on 1 January 2023 and its income for the year to 31 December 2024 was £271,803 (2023 - £289,629). The subsidiary gifts its taxable profit to Anaphylaxis UK and consequently it had no reserves at 31 December 2024 other than its share capital of £1.

Listed fixed asset investments are revalued each year by the external fund managers.

ANAPHYLAXIS UK

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

15. Stocks		31.12.24	31.12.23
		£	£
Finished goods		-	311
		<u> </u>	<u> </u>
16. Debtors: amounts falling due within one year		31.12.24	31.12.23
		£	£
Trade debtors		3,890	3,784
Amounts owed by group undertakings		130,512	85,643
VAT		5,571	5,105
Prepayments and accrued income		38,686	45,801
Accrued income		22,915	9,712
		<u> </u>	<u> </u>
		<u>201,574</u>	<u>150,045</u>
17. Creditors: amounts falling due within one year		31.12.24	31.12.23
		£	£
Trade creditors		39,262	39,960
Social security and other taxes		7,739	6,625
Accruals and deferred income		12,050	1,948
Accrued expenses		7,905	7,805
		<u> </u>	<u> </u>
		<u>66,956</u>	<u>56,338</u>
18. Movement in funds			
		Net	At
	At 1.1.24	movement	31.12.24
	£	in funds	£
		£	
Unrestricted funds			
General fund	629,729	76,698	706,427
Restricted funds			
Isle of Man Fund	-	2,138	2,138
	<u> </u>	<u> </u>	<u> </u>
TOTAL FUNDS	<u>629,729</u>	<u>78,836</u>	<u>708,565</u>

ANAPHYLAXIS UK

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

18. Movement in funds - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	631,514	(565,698)	10,882	76,698
Restricted funds				
Isle of Man Fund	2,138	-	-	2,138
TOTAL FUNDS	<u>633,652</u>	<u>(565,698)</u>	<u>10,882</u>	<u>78,836</u>

Comparatives for movement in funds

	At 1.1.23 £	Net movement in funds £	At 31.12.23 £
Unrestricted funds			
General fund	613,648	16,081	629,729
TOTAL FUNDS	<u>613,648</u>	<u>16,081</u>	<u>629,729</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	586,097	(579,487)	9,471	16,081
TOTAL FUNDS	<u>586,097</u>	<u>(579,487)</u>	<u>9,471</u>	<u>16,081</u>

ANAPHYLAXIS UK

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

18. Movement in funds - continued

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.23 £	Net movement in funds £	At 31.12.24 £
Unrestricted funds			
General fund	613,648	92,779	706,427
Restricted funds			
Isle of Man Fund	-	2,138	2,138
TOTAL FUNDS	<u>613,648</u>	<u>94,917</u>	<u>708,565</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	1,217,611	(1,145,185)	20,353	92,779
Restricted funds				
Isle of Man Fund	2,138	-	-	2,138
TOTAL FUNDS	<u>1,219,749</u>	<u>(1,145,185)</u>	<u>20,353</u>	<u>94,917</u>

19. Related party disclosures

In October 2022 a subsidiary company, Anaphylaxis UK Trading Ltd, was formed. This subsidiary commenced trading in 2023. In the year to 31 December 2024 the subsidiary had income of £271,803 (2023 - £289,629). In accordance with the agreement between the two entities, the whole of Anaphylaxis UK Trading Ltd's taxable profit of £183,240 (2023 - £258,889) was paid to Anaphylaxis UK.

ANAPHYLAXIS UK

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2024**

	31.12.24	31.12.23
	£	£
Income and endowments		
Donations and legacies		
Donations - members	25,304	27,638
Memoriam donations	30,718	19,828
Gift aid	37,599	27,636
Community fundraising & events	43,954	46,233
Charitable trusts and major donors	62,300	20,600
Corporate donations	11,862	7,135
Legacies	-	501
Individual membership	41,715	43,876
Professional membership	155	2,443
Other including Google Adwords	107,556	96,733
Income from subsidiary	183,240	258,889
	<u>544,403</u>	<u>551,512</u>
Other trading activities		
Event income	40,631	15,322
Special project income	37,500	12,380
Other sundry income	361	-
Corporate sponsorship	-	3,500
	<u>78,492</u>	<u>31,202</u>
Investment income		
Dividends and interest rec'd	10,757	3,383
	<u>10,757</u>	<u>3,383</u>
Total incoming resources	633,652	586,097
Expenditure		
Raising donations and legacies		
Wages	95,753	26,269
Other fundraising costs	7,311	10,650
	<u>103,064</u>	<u>36,919</u>
Charitable activities		
Wages	154,125	184,957
Shop and activity purchases	85,378	92,745
Contractor costs	10,048	19,695
Conference and events	5,370	1,636
Special projects	5,303	6,343
	<u>260,224</u>	<u>305,376</u>

This page does not form part of the statutory financial statements

ANAPHYLAXIS UK

**DETAILED STATEMENT OF FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 DECEMBER 2024**

	31.12.24	31.12.23
	£	£
Charitable activities		
Other		
Loss on sale of tangible fixed assets	214	3,946
Support costs		
General costs		
Wages	35,429	67,598
Rent and rates	3,600	7,705
Computer and software costs	48,415	45,246
Telephone	1,372	5,983
Travel and subsistence	3,188	2,150
Recruitment and redundancy	18,979	421
Staff training	5,971	2,034
Office expenses	229	1,091
Stationery and printing	840	620
Postage and carriage	591	246
Professional fees	5,572	2,119
Website costs	1,583	1,524
Insurance	1,981	2,018
Irrecoverable VAT	16,506	22,745
Sundry	357	10,627
Bank charges	2,631	6,340
Plant and machinery	22,027	21,456
	<u>169,271</u>	<u>199,923</u>
Governance costs		
Wages	28,125	26,823
Accountancy and legal fees	4,800	6,500
	<u>32,925</u>	<u>33,323</u>
Total resources expended	<u>565,698</u>	<u>579,487</u>
Net income	<u><u>67,954</u></u>	<u><u>6,610</u></u>

This page does not form part of the statutory financial statements

ANAPHYLAXIS UK

England & Wales - Charity number 1085527

Accounts

REGISTERED COMPANY NUMBER: 04133242 (England and Wales)
REGISTERED CHARITY NUMBER: 1085527

Report of the Trustees and
Unaudited Financial Statements for the Year Ended 31 December 2023
for
Anaphylaxis UK

Chamberlains Chartered Accountants
Elm House, Tanshire Park
Shackleford Road, Elstead
Godalming
Surrey
GU8 6LB

Anaphylaxis UK

Contents of the Financial Statements
for the Year Ended 31 December 2023

	Page
Report of the Trustees	1 to 8
Independent Examiner's Report	9
Statement of Financial Activities	10
Balance Sheet	11 to 12
Cash Flow Statement	13
Notes to the Cash Flow Statement	14
Notes to the Financial Statements	15 to 23
Detailed Statement of Financial Activities	24 to 25

Anaphylaxis UK

Report of the Trustees
for the Year Ended 31 December 2023

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

The Trustees, who are also the Directors of the Charity for the purposes of the Companies Act, are pleased to present their report, together with the annual financial statements for the year ended 31 December 2023.

2023 - A Year of Remarkable Achievements and Unwavering Performance

Collaborating with Healthcare and Allergy Services

- We had the privilege of attending the prestigious BSACI conference in October 2023, where we presented a talk on alpha-gal allergy, shedding light on this critical emerging issue.
- Developed a comprehensive new information booklet on Alpha-gal allergy, featuring compelling case studies and a comprehensive factsheet, empowering individuals with essential knowledge.
- Created four visually captivating posters on best practices in prescribing AAIs, based on the 'Public Assessment Report of the Commission on Human Medicines' Adrenaline Auto-injector Expert Working Group: Recommendations to support the effective and safe use of adrenaline auto-injectors.
- Collaborated with Viatrix on their inspiring Ready2React campaign, fostering a deeper understanding of the profound impact of living with allergies.
- Served as an active member of the BRIT Registry (British Registry for Immunotherapy) steering group, contributing our expertise to support improved outcomes for patients undergoing immunotherapy.
- Actively participated in CYANS (The Children and Young People's Allergy Network Scotland) ensuring the voices of children and young people are heard and their needs are addressed.
- Developed a suite of podcasts, featuring our Chief Executive, Simon Williams, engaging in thought-provoking discussions with both healthcare professionals and members of the public affected by allergies.
- Dr Helen Evans-Howells (trustee) was appointed as the esteemed chair of our clinical and scientific panel, working tirelessly with clinical colleagues to gain further engagement in the vital work of Anaphylaxis UK.
- We published a monthly healthcare professionals' newsletter, keeping healthcare professionals informed about the latest developments in allergy and resources for their patients. This newsletter boasted an impressive opening rate of above 70%, reflecting its invaluable content.

Health-related Research

- We collaborated with Southampton University (Professor Graham Roberts) on the groundbreaking 'Preventing food allergy in infants with early introduction of complementary feeding study.'
- Partnered with The University of Birmingham on the FAIR Study (Food Allergy Inequality Research), 'Addressing inequalities in the management of food allergy in South Asian adults,' a critical endeavour to promote inclusivity and equity.
- Actively promoted research initiatives at Aston University and supported PhD Students, fostering the advancement of scientific knowledge.

Anaphylaxis UK

Report of the Trustees for the Year Ended 31 December 2023

Patient Information

- Achieved the prestigious re-accreditation for our patient information factsheets from the Patient Information Forum (PIF) Tick quality mark in November 2023, a testament to our unwavering commitment to providing accurate and reliable information.
- Continued the extensive review and redevelopment of our entire library of factsheets, aligning them with our new updated website and brand guidelines, ensuring a cohesive and visually appealing experience for our audience.
- Recruited 50 new lay reviewers to lend their invaluable perspectives and contribute to the review process of our factsheets, ensuring a comprehensive and user-friendly approach.
- Collaborated with the MHRA on their AAI Safety Campaign, raising public awareness about the safe and effective use of AAIs.
- Responded to over 500 calls and over 1,200 emails on our dedicated helpline, providing personalized support and guidance to individuals in need.
- Updated our method of logging helpline enquiries, transitioning from a Microsoft database to the Feedback module on CRM, enhancing our ability to analyse calls and improve the support we offer.
- Our popular Bee and Wasp Campaign returned triumphantly, running from May to September. We worked hand-in-hand with beekeeping societies across all four nations, developing a range of invaluable information resources to support the venom-allergic community. This included a captivating podcast with Dr Andrew Whyte, which garnered an impressive 5,500 views, a testament to its resonance and relevance.

AllergyWise Training Program

- Relaunched our AllergyWise training courses on the new LearnDash platform, boasting a fresh look and updated content, ensuring our offerings remain cutting-edge and engaging.
- Introduced new courses tailored for Out of School Settings and Workplaces, expanding our reach and impact.
- Created new information resources to complement our course content, including risk assessments and practical scenarios, providing a comprehensive learning experience.
- Celebrated a remarkable 135% improvement in AllergyWise School course sales, soaring from £50,788 to an impressive £119,151, reflecting the increasing demand for our high-quality educational offerings.
- Achieved a 12% improvement in AllergyWise sales for Healthcare Professionals, Care Workers, Out of School Settings, and Workplace courses, rising from £17,170 to £19,298, a testament to the trust and confidence placed in our programs.

Communications

Social media

- Our Facebook following grew to 20,000 with an impressive reach of 1.4 million, reflecting the resonance of our message and the strength of our online community.
- Our Instagram following witnessed remarkable growth, reaching 7,900 and a reach of 157,000, showcasing the visual appeal of our content and the engagement of our audience.
- Our LinkedIn presence flourished, with our followers growing to 1,800, fostering valuable professional connections and thought leadership.

Anaphylaxis UK

Report of the Trustees
for the Year Ended 31 December 2023

Newsletters

AllergyOutlook is our popular monthly newsletter featuring articles and news written to support people with allergies. The newsletter shines a spotlight on the tireless efforts of our charity, keeping subscribers informed about the latest initiatives, groundbreaking services, and the tangible impact we are making in the lives of individuals and families. In the past year alone, our subscriber base has flourished, expanding from 4,600 to 13,000, an astonishing achievement in the period..

Fundraising Highlights

- Our remarkable London Marathon 2023 runners exceeded their combined fundraising target by an astonishing 35%. We were fortunate to have an additional three ballot runners join our strong team of five, and collectively, they raised an impressive £15,322, a true testament to their dedication and the generosity of our supporters and all those involved with them.

- A new and innovative fundraising challenge, #Challenge14, was created for Anaphylaxis Awareness Week 2023. This campaign invited supporters to fundraise in unique ways, incorporating the number 14 (e.g., repetitions, distance, donation ask value) within their challenge to raise awareness of the 14 major food allergens. We were humbled by the participation of 24 individuals - including beneficiaries, staff, trustees, schools, corporates, and suppliers - who collectively raised an incredible £6,245 (excluding Gift Aid), demonstrating the power of community and collective action.

- For the first time, Anaphylaxis UK participated in Big Give's Christmas Challenge 2023, the UK's largest match-funded campaign. Our "A brighter future for people with serious allergies" campaign aimed to raise £10,000 from supporter pledges, match funding, and public donations. Within the week-long campaign, we not only achieved our target but exceeded it, raising a remarkable total of £10,284, a testament to the generosity and commitment of our supporters.

FUNDRAISER FOCUS: #Challenge14 Participants

The participants of the inaugural #Challenge14 fundraising event truly embodied the spirit of determination and compassion, each undertaking a unique challenge to raise awareness of the 14 major food allergens. Among the standout fundraisers were:

- Lucy, a devoted mother, who raised an incredible £435 on a 14-mile walk in support of her young daughter's journey with allergies.

- George, an 11-year-old with unwavering dedication, raised £310 by washing 14 cars in 7 days, demonstrating that age is no barrier to making a difference.

- Our corporate sponsor, Nestle Health Science, contributed £664 to the fundraising pot through a lively quiz night and sweepstake, showcasing their commitment to our cause.

- Saoirse, a young student, presented a school assembly to her classmates and walked an impressive 14km over 7 days, raising £98 and fostering awareness among her peers.

FUNDRAISER FOCUS: 10 Years of Celebrating Will

For the past decade, friends and family of Will, who tragically passed away in 2013, have organised an annual charity golf day to raise funds for Anaphylaxis UK. To mark this significant anniversary, the 2023 event was bigger and better than ever, with 34 players and 60 evening guests, raising over £3,000. Over the last 10 years, an extraordinary £15,000 has been generously raised by Will's loved ones, honouring his memory and supporting our mission through their greatly appreciated efforts.

Anaphylaxis UK

Report of the Trustees for the Year Ended 31 December 2023

FUNDRAISER FOCUS: Charity Football Day

In a poignant and heartwarming tribute, friends and family came together in April 2023 to celebrate the memory of James, who tragically passed away from anaphylaxis in February 2018 at the age of 15. On what would have been his 21st birthday, they organised a charity football day, raffle, and auction for Anaphylaxis UK. The event was a resounding success, raising a staggering £5,857 on the day to celebrate James.

Impactful Contributions

The generosity of our supporters has been truly awe-inspiring. Driven by an unwavering dedication to our cause, major donors contributed a remarkable £7,000, providing invaluable support that propelled our ongoing efforts forward. Additionally, we are deeply humbled by the £19,828 raised through heartfelt in memoriam donations, profound tributes that honour the memories of loved ones and underscore the profound impact of our work.

Public donations, totalling an extraordinary £48,305, have been instrumental in fuelling our mission, enabling us to provide vital support services, education and advocacy for individuals and families affected by allergies. These contributions represent more than just financial assistance; they are a testament to the trust and belief our community has placed in us.

Driving Change through Grants

Grants totalling £13,600 have been catalysts for our initiatives, empowering us to keep the allergy community safe and supported. Funding from esteemed Trusts such as The Brian Shaw Memorial Trust, The Ardwick Trust, and The Lady Hind Trust has enabled our information and services team to deliver essential support services to the public, ensuring that no one faces the challenges of allergies alone or without guidance.

Moreover, grants from the CRH Charitable Trust, The Anton Jurgens Charitable Trust, and the Hospital Saturday Fund have paved the way for the development of our pioneering AllergyWise training for Early Years settings. This groundbreaking initiative equips caregivers and educators with the knowledge and tools necessary to create safer environments for children with allergies, fostering inclusivity and protection from a young age.

Anaphylaxis UK Business Symposium

This flagship event, held at the renowned Francis Crick Institute in London in December 2023, was a resounding success. We raised an impressive £26,500 from sponsors of the business symposium, with generous contributions from esteemed partners including RSSL, SGS, ServeLegal, Romer Labs, Neogen, Thermo Fisher Scientific, DBV Technologies, and Christeyns Food Hygiene. This significant support has bolstered our initiatives, enabling us to advance our mission of fostering inclusion and awareness within society.

Additionally, our corporate members' unwavering commitment generated an incredible £75,885 through their memberships. Their partnership has been instrumental in driving positive change and expanding our outreach efforts, amplifying our impact and ensuring our message resonates far and wide.

Through the collective efforts of our dedicated supporters, tireless volunteers, and passionate team members, we have achieved remarkable milestones in 2023. These achievements are not merely statistics or figures; they represent lives transformed, hope rekindled, and a future where individuals with allergies can live with confidence, empowerment, and a profound sense of community.

As we look ahead, we are filled with renewed determination and optimism, fuelled by the successes of the past year and the unwavering commitment. Together, we will continue to forge ahead, advocating for change, raising awareness, and ensuring that no one faces the challenges of allergies alone.

Anaphylaxis UK

Report of the Trustees
for the Year Ended 31 December 2023

Investment performance achieved against investment objectives

The investment objectives of the Charity are to maximise the value of reserves, while avoiding undue risk. The Charity's policy on investment includes a requirement to limit investments to 60% of liquid assets and only to invest in Funds regulated by the Financial Conduct Authority. The Charity's investments in an Income and Growth portfolio with Hargreaves Lansdown showed a gain of £9,471 on the value report at the end of December 2022 (£154,824). The value at the end of December 2023 was £164,295.

Financial review: Reserves policy

To achieve a sound balance between prudence and ensuring funds are expended in achieving the objectives of the Charity, the Trustees have established a policy whereby the unrestricted reserves held by the Charity should equate to at least six months operating costs. At the year end this equated to £245,182. Free reserves (excluding 6 months operating costs) at 31 December 2023 stood at £386,685.

Restricted reserves

There were no restricted reserves at 31 December 2023.

Risk review

The Trustees have conducted a review of the major risks to which the Charity is exposed and systems have been established to manage those risks. A risk management register is maintained and risks highlighted are reviewed regularly to ensure they do not pose a threat to the Charity going forward. Key risks for the Charity include an uncertain economic outlook and its impact on fundraising by individuals and financial support from businesses.

Financial overview

The Charity ended the year in a sound financial position with sufficient free reserves to meet its reserves policy. Net outgoing resources for the year amounted to £579,487. Unrestricted funds were £631,867 and restricted funds were zero.

Financial policies

All payments up to £10,000 made by the Charity have to be signed by two authorised signatories and by a Trustee in addition for payments over that amount. The day-to-day management of the financial affairs of the Charity is delegated to the Head of Finance and Operations who submits Management Accounts and a written report monthly to the CEO and Board of Trustees. A financial report supported by Management Accounts is delivered at each meeting of Trustees.

Principal funding sources

The principal funding sources for the charity are community fundraising initiatives such as the London Marathon, sales from our AllergyWise training programme and from Business Membership. The charity also benefits from grants and sponsorship of project work such as awareness campaigns.

Use of funds

Funds received by the charity have contributed significantly to the expansion of services offered by the Information Team and in our ability to enhance our awareness campaigns to reach more people with allergies.

Anaphylaxis UK

Report of the Trustees
for the Year Ended 31 December 2023

Plans for the future

The Board have agreed a Strategic Framework for 2023-2028. The general impact the Anaphylaxis UK charity aims to achieve by the end of 2028 is:

We want everyone with a serious allergy to enjoy the same quality of life as someone without an allergy. Over the next five years, all of our work will focus on making this ambition a reality.

Our main priority areas and the impact we aim to achieve within each area are set out in the Business Plan since they were approved by the Board in March 2023. The main areas for future work are:

- Empowering Lives, Conquering Fears in the Years Ahead

For too long, the anxiety of living with an allergy has robbed individuals of the freedom to fully embrace life's cherished moments - from joyous birthday celebrations to simple acts of socialising and exploring the world around them. The ever-present fear of a potential reaction has cast a shadow over the everyday, creating an unacceptable barrier to living life to the fullest. But today, we stand united in our resolve to shatter those barriers and empower our community to reclaim their lives without fear.

Following the success of a groundbreaking Knowledge Transfer (KTP) grant, we are thrilled to announce an unprecedented partnership with the esteemed University of Surrey. Together, we will embark on an ambitious journey, collaborating with renowned clinical psychologists to develop a transformative support system. This pioneering program will equip individuals with the tools and strategies to conquer their anxieties, empowering them with the skills to navigate life's adventures with confidence and resilience.

This visionary initiative marks a milestone in the evolution of our charity, as we expand our horizons to offer life-changing services tailored to the unique needs of our beneficiaries. No longer will fear dictate their choices; instead, they will be equipped with the knowledge and self-assurance to embrace every opportunity, every moment, and every dream.

- Safer Schools, Brighter Futures

Recognising the pivotal role of educational institutions in fostering an inclusive and supportive environment, we will expand our acclaimed AllergyWise portfolio, with a particular emphasis on our Safer Schools Programme. Through this initiative, we will actively encourage more schools to undertake comprehensive training and adopt robust policies and procedures, ensuring that every student with allergies can learn, grow, and thrive in a nurturing and secure environment.

- Forging Powerful Partnerships

In our unwavering pursuit of promoting awareness and understanding, we will enhance our relationships with leading businesses, forging powerful partnerships that amplify our collective impact. Together, we will embark on groundbreaking awareness-raising programs, fostering a culture of inclusion and empathy that transcends boundaries.

- Empowering Businesses, Enriching Lives

Recognising the vital role that small and medium-sized enterprises play in shaping our communities, we will develop an innovative online portal - a comprehensive resource tailored to their unique needs. This dynamic platform will serve as a trusted guide, providing factually accurate support, resources, and insights to help businesses navigate the complexities of allergies with ease. From developing allergy-aware products and services to fostering inclusive practices, we will empower these enterprises to become catalysts for positive change, creating a world where accessibility and understanding are woven into the very fabric of society.

Anaphylaxis UK

Report of the Trustees
for the Year Ended 31 December 2023

- Accessible Information, Trusted Source

Our commitment to providing accurate and trusted information will reach new heights as we embrace diverse mediums to cater to the evolving needs of our beneficiaries. Through captivating infographics, engaging animations, and informative videos, we will ensure that our factsheets and resources are not only informative but also accessible and engaging. By meeting our community where they are, we will solidify our position as the premier trusted source of information, empowering individuals to make informed decisions and navigate their journey with confidence.

Together, we stand at the precipice of a transformative era, where the weight of anxiety is lifted, and the freedom to embrace life's every opportunity is within reach.

Statement of Trustees' responsibilities

The trustees (who are also directors of the Charity for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent Examiners

Chamberlains were appointed independent at the Annual General Meeting of the Charity held on 10th June 2024.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

04133242 (England and Wales)

Anaphylaxis UK

Report of the Trustees
for the Year Ended 31 December 2023

Registered Charity number
1085527


Registered office
1 Alexandra Road
Farnborough
GU14 6BU

Trustees
Dr A M Walker-Fraser Chair
Mr P M Littleton Vice Chair
Mr C Meads (resigned 8.6.23)
Mrs T Randhawa
Mrs L C Wilkinson
Mrs S C Hall (resigned 10.4.24)
Dr H E Evans-Howells
Mr R J Wright KC
Mr B Gaventa (resigned 10.3.23)
Ms C C A Fearnley (appointed 17.7.23)

Company Secretary
Mrs L A Ingram

Independent Examiner
Paul J Chamberlain FCA DChA
Chamberlains Chartered Accountants
Elm House, Tanshire Park
Shackleford Road, Elstead
Godalming
Surrey
GU8 6LB

Approved by order of the board of trustees on 12 June 2024 and signed on its behalf by:

DocuSigned by:

.....1C4B1FCD180E469.....
Dr A M Walker-Fraser - Trustee

Independent Examiner's Report to the Trustees of
Anaphylaxis UK

Independent examiner's report to the trustees of Anaphylaxis UK ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2023.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.


Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

DocuSigned by:


CAB9802C14504F6...
Paul J Chamberlain FCA DChA
The Institute of Chartered Accountants in England and Wales

Chamberlains Chartered Accountants
Elm House, Tanshire Park
Shackleford Road, Elstead
Godalming
Surrey
GU8 6LB

Date: 12 June 2024
Date:

Anaphylaxis UKStatement of Financial Activities
for the Year Ended 31 December 2023

	Notes	Unrestricted fund £	Restricted funds £	31.12.23 Total funds £	31.12.22 Total funds £
INCOME FROM					
Donations and legacies	2	551,512	-	551,512	354,712
Charitable activities					
Sale of educational products	5	-	-	-	68,116
Product recall income		-	-	-	42,902
Other trading activities	3	31,202	-	31,202	73,134
Investment income	4	3,383	-	3,383	2,030
Total		<u>586,097</u>	<u>-</u>	<u>586,097</u>	<u>540,894</u>
EXPENDITURE ON					
Raising funds	6	79,256	-	79,256	76,821
Charitable activities					
Charitable activities	7	496,285	-	496,285	421,369
Other		3,946	-	3,946	31,347
Total		<u>579,487</u>	<u>-</u>	<u>579,487</u>	<u>529,537</u>
Net gains/(losses) on investments		<u>9,471</u>	<u>-</u>	<u>9,471</u>	<u>(8,078)</u>
NET INCOME		16,081	-	16,081	3,279
RECONCILIATION OF FUNDS					
Total funds brought forward		613,648	-	613,648	610,369
TOTAL FUNDS CARRIED FORWARD		<u><u>629,729</u></u>	<u><u>-</u></u>	<u><u>629,729</u></u>	<u><u>613,648</u></u>

The notes form part of these financial statements

Anaphylaxis UKBalance Sheet31 December 2023

	Notes	Unrestricted fund £	Restricted funds £	31.12.23 Total funds £	31.12.22 Total funds £
FIXED ASSETS					
Intangible assets	13	37,963	-	37,963	43,183
Tangible assets	14	10,933	-	10,933	15,035
Investments	15	164,296	-	164,296	154,824
		<u>213,192</u>	<u>-</u>	<u>213,192</u>	<u>213,042</u>
CURRENT ASSETS					
Stocks	16	311	-	311	828
Debtors	17	150,045	-	150,045	70,689
Cash in hand		322,519	-	322,519	373,041
		<u>472,875</u>	<u>-</u>	<u>472,875</u>	<u>444,558</u>
CREDITORS					
Amounts falling due within one year	18	(56,338)	-	(56,338)	(43,952)
		<u>416,537</u>	<u>-</u>	<u>416,537</u>	<u>400,606</u>
NET CURRENT ASSETS					
		<u>416,537</u>	<u>-</u>	<u>416,537</u>	<u>400,606</u>
TOTAL ASSETS LESS CURRENT LIABILITIES					
		<u>629,729</u>	<u>-</u>	<u>629,729</u>	<u>613,648</u>
NET ASSETS					
		<u>629,729</u>	<u>-</u>	<u>629,729</u>	<u>613,648</u>
FUNDS					
Unrestricted funds	19			629,729	613,648
TOTAL FUNDS					
				<u>629,729</u>	<u>613,648</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.


The notes form part of these financial statements

Anaphylaxis UK

Balance Sheet - continued
31 December 2023

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on
12 June 2024
..... and were signed on its behalf by:

DocuSigned by:

.....1C4B1FCD180E469.....
Dr A M Walker-Fraser - Trustee

Anaphylaxis UKCash Flow Statementfor the Year Ended 31 December 2023

	Notes	31.12.23 £	31.12.22 £
Cash flows from operating activities			
Cash generated from operations	1	(37,824)	19,714
Net cash (used in)/provided by operating activities		<u>(37,824)</u>	<u>19,714</u>
Cash flows from investing activities			
Purchase of intangible fixed assets		(12,632)	(45,670)
Purchase of tangible fixed assets		(3,448)	(8,909)
Purchase of fixed asset investments		(1)	-
Sale of intangible fixed assets		2,950	-
Sale of tangible fixed assets		(2,950)	5,265
Interest received		3,383	2,030
Net cash used in investing activities		<u>(12,698)</u>	<u>(47,284)</u>
Change in cash and cash equivalents in the reporting period			
		(50,522)	(27,570)
Cash and cash equivalents at the beginning of the reporting period			
		<u>373,041</u>	<u>400,611</u>
Cash and cash equivalents at the end of the reporting period			
		<u><u>322,519</u></u>	<u><u>373,041</u></u>

The notes form part of these financial statements

Anaphylaxis UKNotes to the Cash Flow Statement
for the Year Ended 31 December 2023

1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES	31.12.23	31.12.22
	£	£
Net income for the reporting period (as per the Statement of Financial Activities)	16,081	3,279
Adjustments for:		
Depreciation charges	21,456	15,710
(Gain)/losses on investments	(9,471)	8,078
Loss on disposal of fixed assets	3,946	-
Interest received	(3,383)	(2,030)
Decrease in stocks	517	2,379
Increase in debtors	(79,357)	(13,551)
Increase in creditors	12,387	5,849
	<u>(37,824)</u>	<u>19,714</u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.23	Cash flow	At 31.12.23
	£	£	£
Net cash			
Cash at bank and in hand	373,041	(50,522)	322,519
	<u>373,041</u>	<u>(50,522)</u>	<u>322,519</u>
Total	<u>373,041</u>	<u>(50,522)</u>	<u>322,519</u>

The notes form part of these financial statements

Anaphylaxis UKNotes to the Financial Statements
for the Year Ended 31 December 2023**1. ACCOUNTING POLICIES****Basis of preparing the financial statements**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

Preparation of consolidated financial statements

The financial statements contain information about Anaphylaxis UK as an individual company and do not contain consolidated financial information as the parent of a group. The charity is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Anaphylaxis UK has one subsidiary, Anaphylaxis UK Trading Ltd. The registered office of the subsidiary is 1 Alexandra Road, Farnborough, GU14 6BU. Anaphylaxis UK owns 100% of the £1 ordinary share capital of the subsidiary.

The subsidiary company carries out trading activities related to the objectives of Anaphylaxis UK. All the taxable profits of the subsidiary are paid by gift to Anaphylaxis UK and are used in the furtherance of the charity's objectives. Consequently, the total reserves of the subsidiary are its £1 ordinary share capital.

Total income and expenditure of the subsidiary in the year to 31 December 2023 were £264,800, including ££200,940 paid by gift to Anaphylaxis UK.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery - 25% on cost

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Anaphylaxis UKNotes to the Financial Statements - continued
for the Year Ended 31 December 2023**1. ACCOUNTING POLICIES - continued****Fund accounting**

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease.

Investments

Fixed asset investments are treated as a single asset, revalued each year to current market value.

2. DONATIONS AND LEGACIES

	31.12.23	31.12.22
	£	£
Donations - members	27,638	29,595
Memoriam donations	19,828	30,151
Gift aid	27,636	37,906
Community fundraising & events	46,233	23,386
Charitable trusts and major donors	20,600	38,600
Corporate donations	7,135	8,825
Legacies	501	13,986
Individual membership	43,876	47,433
Professional membership	2,443	3,096
Corporate membership	-	57,955
Other including Google Adwords	96,733	63,779
Income from subsidiary	258,889	-
	<u>551,512</u>	<u>354,712</u>

Since 1 January 2023 a number of activities previously undertaken by Anaphylaxis UK have been carried out by its subsidiary, Anaphylaxis UK Trading Ltd. These include corporate membership, Allergywise training, product recall work, events, special projects and some other activities. All of Anaphylaxis UK Trading Ltd's surplus for the year is gifted to Anaphylaxis UK and is included in Donations and Legacies.

3. OTHER TRADING ACTIVITIES

	31.12.23	31.12.22
	£	£
Shop income	-	909
Event income	15,322	16,441
Special project income	12,380	43,700
Other sundry income	-	8,784
Corporate sponsorship	3,500	3,300
	<u>31,202</u>	<u>73,134</u>

Anaphylaxis UKNotes to the Financial Statements - continued
for the Year Ended 31 December 2023**4. INVESTMENT INCOME**

	31.12.23	31.12.22
	£	£
Dividends and interest rec'd	3,383	2,030
	<u> </u>	<u> </u>

5. INCOME FROM CHARITABLE ACTIVITIES

The split of income from charitable activities is shown in the Statement of Financial Activities.

6. RAISING FUNDS**Raising donations and legacies**

	31.12.23	31.12.22
	£	£
Staff costs	26,269	24,224
Other fundraising costs	10,650	9,457
Support costs	42,337	43,140
	<u> </u>	<u> </u>
	<u>79,256</u>	<u>76,821</u>

7. CHARITABLE ACTIVITIES COSTS

	Direct Costs £	Support costs (see note 8) £	Totals £
Charitable activities	305,376	190,909	496,285
	<u> </u>	<u> </u>	<u> </u>

8. SUPPORT COSTS

	General costs £	Governance costs £	Totals £
Raising donations and legacies	42,337	-	42,337
Charitable activities	157,586	33,323	190,909
	<u> </u>	<u> </u>	<u> </u>
	<u>199,923</u>	<u>33,323</u>	<u>233,246</u>

9. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	31.12.23	31.12.22
	£	£
Audit fee	-	5,150
Auditor's remuneration for other work	-	750
Depreciation - owned assets	6,554	5,880
Hire of plant and machinery	7,705	8,775
Other operating leases	45,246	34,723
Deficit on disposal of fixed assets	3,946	-
Computer software amortisation	14,902	9,830
	<u> </u>	<u> </u>

Anaphylaxis UKNotes to the Financial Statements - continued
for the Year Ended 31 December 2023**10. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31 December 2023 nor for the year ended 31 December 2022.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 December 2023 nor for the year ended 31 December 2022.

11. STAFF COSTS

	31.12.23	31.12.22
	£	£
Wages and salaries	305,647	286,898
	<u>305,647</u>	<u>286,898</u>

The average monthly number of employees during the year was as follows:

	31.12.23	31.12.22
Fundraising	1	1
Charitable activities	7	7
	<u>8</u>	<u>8</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	31.12.23	31.12.22
£60,001 - £70,000	-	1
£70,001 - £80,000	1	-
	<u>1</u>	<u>1</u>

12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted funds £	Total funds £
INCOME FROM			
Donations and legacies	354,712	-	354,712
Charitable activities			
Sale of educational products	68,116	-	68,116
Product recall income	42,902	-	42,902
Other trading activities	73,134	-	73,134
Investment income	2,030	-	2,030
Total	<u>540,894</u>	<u>-</u>	<u>540,894</u>
EXPENDITURE ON			
Raising funds	76,821	-	76,821
Charitable activities			
Charitable activities	418,226	3,143	421,369

Anaphylaxis UKNotes to the Financial Statements - continued
for the Year Ended 31 December 2023**12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued**

	Unrestricted fund £	Restricted funds £	Total funds £
Other	31,347	-	31,347
Total	<u>526,394</u>	<u>3,143</u>	<u>529,537</u>
Net gains/(losses) on investments	<u>(8,078)</u>	<u>-</u>	<u>(8,078)</u>
NET INCOME/(EXPENDITURE)	6,422	(3,143)	3,279
RECONCILIATION OF FUNDS			
Total funds brought forward	607,226	3,143	610,369
TOTAL FUNDS CARRIED FORWARD	<u><u>613,648</u></u>	<u><u>-</u></u>	<u><u>613,648</u></u>

13. INTANGIBLE FIXED ASSETS

	Computer software £
COST	
At 1 January 2023	58,911
Additions	12,632
Disposals	(13,241)
At 31 December 2023	<u>58,302</u>
AMORTISATION	
At 1 January 2023	15,728
Charge for year	14,902
Eliminated on disposal	(10,291)
At 31 December 2023	<u>20,339</u>
NET BOOK VALUE	
At 31 December 2023	<u><u>37,963</u></u>
At 31 December 2022	<u><u>43,183</u></u>

Anaphylaxis UKNotes to the Financial Statements - continued
for the Year Ended 31 December 2023**14. TANGIBLE FIXED ASSETS**

	Plant and machinery £
COST	
At 1 January 2023	37,850
Additions	3,448
Disposals	(15,409)
At 31 December 2023	<u>25,889</u>
DEPRECIATION	
At 1 January 2023	22,815
Charge for year	6,554
Eliminated on disposal	(14,413)
At 31 December 2023	<u>14,956</u>
NET BOOK VALUE	
At 31 December 2023	<u><u>10,933</u></u>
At 31 December 2022	<u><u>15,035</u></u>

15. FIXED ASSET INVESTMENTS

	Shares in group undertakings £	Listed investments £	Totals £
MARKET VALUE			
At 1 January 2023	-	154,824	154,824
Additions	1	-	1
Revaluations	-	9,471	9,471
At 31 December 2023	<u>1</u>	<u>164,295</u>	<u>164,296</u>
NET BOOK VALUE			
At 31 December 2023	<u><u>1</u></u>	<u><u>164,295</u></u>	<u><u>164,296</u></u>
At 31 December 2022	<u><u>-</u></u>	<u><u>154,824</u></u>	<u><u>154,824</u></u>

There were no investment assets outside the UK.

Anaphylaxis UK holds the entire £1 share capital of its trading subsidiary Anaphylaxis UK Trading Ltd. The subsidiary began trading on 1 January 2023 and its income for the year to 31 December 2023 was £289,629. The subsidiary gifts its taxable profit to Anaphylaxis UK and consequently it had no reserves at 31 December 2023 other than its share capital of £1.

Listed fixed asset investments are revalued each year by the external fund managers.

Anaphylaxis UKNotes to the Financial Statements - continued
for the Year Ended 31 December 2023**16. STOCKS**

	31.12.23	31.12.22
	£	£
Finished goods	311	828
	<u> </u>	<u> </u>

17. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.12.23	31.12.22
	£	£
Trade debtors	3,784	23,449
Amounts owed by group undertakings	85,643	-
VAT	5,105	2,190
Prepayments and accrued income	45,801	36,903
Accrued income	9,712	8,147
	<u> </u>	<u> </u>
	<u>150,045</u>	<u>70,689</u>

18. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.12.23	31.12.22
	£	£
Trade creditors	39,960	29,564
Social security and other taxes	6,625	5,078
Accruals and deferred income	1,948	2,469
Accrued expenses	7,805	6,841
	<u> </u>	<u> </u>
	<u>56,338</u>	<u>43,952</u>

19. MOVEMENT IN FUNDS

	At 1.1.23	Net movement in funds	At 31.12.23
	£	£	£
Unrestricted funds			
General fund	613,648	16,081	629,729
	<u> </u>	<u> </u>	<u> </u>
TOTAL FUNDS	<u>613,648</u>	<u>16,081</u>	<u>629,729</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	586,097	(579,487)	9,471	16,081
	<u> </u>	<u> </u>	<u> </u>	<u> </u>
TOTAL FUNDS	<u>586,097</u>	<u>(579,487)</u>	<u>9,471</u>	<u>16,081</u>

Anaphylaxis UKNotes to the Financial Statements - continued
for the Year Ended 31 December 2023**19. MOVEMENT IN FUNDS - continued****Comparatives for movement in funds**

	At 1.1.22 £	Net movement in funds £	At 31.12.22 £
Unrestricted funds			
General fund	607,226	6,422	613,648
Restricted funds			
Isle of Man Fund	3,143	(3,143)	-
TOTAL FUNDS	<u>610,369</u>	<u>3,279</u>	<u>613,648</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	540,894	(526,394)	(8,078)	6,422
Restricted funds				
Isle of Man Fund	-	(3,143)	-	(3,143)
TOTAL FUNDS	<u>540,894</u>	<u>(529,537)</u>	<u>(8,078)</u>	<u>3,279</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.22 £	Net movement in funds £	At 31.12.23 £
Unrestricted funds			
General fund	607,226	22,503	629,729
Restricted funds			
Isle of Man Fund	3,143	(3,143)	-
TOTAL FUNDS	<u>610,369</u>	<u>19,360</u>	<u>629,729</u>

Anaphylaxis UKNotes to the Financial Statements - continued
for the Year Ended 31 December 2023**19. MOVEMENT IN FUNDS - continued**

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	1,126,991	(1,105,881)	1,393	22,503
Restricted funds				
Isle of Man Fund	-	(3,143)	-	(3,143)
TOTAL FUNDS	<u>1,126,991</u>	<u>(1,109,024)</u>	<u>1,393</u>	<u>19,360</u>

20. RELATED PARTY DISCLOSURES

In October 2022 a subsidiary company, Anaphylaxis UK Trading Ltd, was formed. This subsidiary commenced trading in 2023. In the year to 31 December 2023 the subsidiary had income of £289,629. In accordance with the agreement between the two entities, the whole of Anaphylaxis UK Trading Ltd's taxable profit of £200,940 was paid to Anaphylaxis UK.

Anaphylaxis UKDetailed Statement of Financial Activities
for the Year Ended 31 December 2023

	31.12.23	31.12.22
	£	£
INCOME		
Donations and legacies		
Donations - members	27,638	29,595
Memoriam donations	19,828	30,151
Gift aid	27,636	37,906
Community fundraising & events	46,233	23,386
Charitable trusts and major donors	20,600	38,600
Corporate donations	7,135	8,825
Legacies	501	13,986
Individual membership	43,876	47,433
Professional membership	2,443	3,096
Corporate membership	-	57,955
Other including Google Adwords	96,733	63,779
Income from subsidiary	258,889	-
	<hr/>	<hr/>
	551,512	354,712
Other trading activities		
Shop income	-	909
Event income	15,322	16,441
Special project income	12,380	43,700
Other sundry income	-	8,784
Corporate sponsorship	3,500	3,300
	<hr/>	<hr/>
	31,202	73,134
Investment income		
Dividends and interest rec'd	3,383	2,030
Charitable activities		
Sale of educational products	-	68,116
Product recall income	-	42,902
	<hr/>	<hr/>
	-	111,018
Total incoming resources		
	586,097	540,894
EXPENDITURE		
Raising donations and legacies		
Wages	26,269	24,224
Other fundraising costs	10,650	9,457
	<hr/>	<hr/>
	36,919	33,681
Charitable activities		
Wages	184,957	188,163
Shop and activity purchases	92,745	84,629
Carried forward	277,702	272,792

This page does not form part of the statutory financial statements

Anaphylaxis UKDetailed Statement of Financial Activities
for the Year Ended 31 December 2023

	31.12.23	31.12.22
	£	£
Charitable activities		
Brought forward	277,702	272,792
Contractor costs	19,695	23,800
Conference and events	1,636	694
Special projects	6,343	5,607
	<hr/>	<hr/>
	305,376	302,893
Other		
Loss on sale of tangible fixed assets	3,946	-
Support costs		
General costs		
Wages	67,598	49,397
Rent and rates	7,705	8,775
Computer and software costs	45,246	34,723
Telephone	5,983	5,412
Travel and subsistence	2,150	2,072
Recruitment and redundancy	421	757
Staff training	2,034	2,074
Office expenses	1,091	2,625
Stationery and printing	620	102
Postage and carriage	246	2,160
Professional fees	2,119	4,678
Website costs	1,524	3,189
Insurance	2,018	2,350
Irrecoverable VAT	22,745	15,447
Sundry	10,627	6,904
Bank charges	6,340	5,241
Plant and machinery	21,456	15,710
	<hr/>	<hr/>
	199,923	161,616
Governance costs		
Wages	26,823	25,114
Auditors' remuneration	-	5,900
Sundries	-	333
Accountancy and legal fees	6,500	-
	<hr/>	<hr/>
	33,323	31,347
Total resources expended	<hr/>	<hr/>
	579,487	529,537
Net income	<hr/>	<hr/>
	6,610	11,357

This page does not form part of the statutory financial statements

ANAPHYLAXIS UK

England & Wales - Charity number 1085527

Accounts

Report of the Trustees and
Financial Statements for the Year Ended 31 December 2022
for
Anaphylaxis UK



Chamberlains Statutory Auditors
and Chartered Accountants
Elm House, Tanshire Park

Contents of the Financial Statements
for the Year Ended 31 December 2022

	Page
Report of the Trustees	1 to 6
Report of the Independent Auditors	7 to 9
Statement of Financial Activities	10
Balance Sheet	11
Cash Flow Statement	12
Notes to the Cash Flow Statement	13
Notes to the Financial Statements	14 to 22
Detailed Statement of Financial Activities	23 to 24

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

The Trustees, who are also the Directors of the Charity for the purposes of the Companies Act, are pleased to present their report, together with the financial statements for the Year ended 31 December 2022.

2022 - ACHIEVEMENTS AND PERFORMANCE

Schools and Universities

o 2022 saw the launch of our new Safer School's Programme which now includes:

- New allergy awareness lesson resources within AllergyWise for Schools
- New AllergyWise school award
- New Allergy awareness assembly presentation for schools

o We promoted the new Safer School's Programme in a mailing to 27,000 schools with an average open rate of 13%.

o We have collaborated with the University of Southampton to conduct a survey to understand the uptake and barriers of spare pens in schools. This was sent to all directors of education across all of England and Wales.

o We held a podcast with Adrian Sie on the topic of nut-free schools in October 2022.

o We presented at the Association for Student Residential Accommodation (ASRA) annual conference with Melissa Singh.

o Mailing to all schools on the Isle of Man with to offer funded AllergyWise for Schools courses which was taken up by 416 staff across 5 schools.

Working with healthcare and allergy services

o We launched a new AllergyWise for Hospital Ward staff course and commenced collaboration with the chair of NHS national standards for healthcare food and drink, with plans for a project in anaphylaxis awareness week 2023.

o Through reaching out to allergy clinics across England and Wales, we have been able to promote AllergyWise for Schools and share our new website and resources for healthcare professionals.

o We developed a new poster with a QR code, promoting our website and resources for primary care to share with their patients.

o We relaunched our healthcare professionals' newsletter which achieved an opening rate of 60%.

o We are members of the Children's and Young People's Allergy Network Scotland (CYANS) through which we helped developed their strategic plan for 2023. CYANS published the latest activity of Anaphylaxis UK in their seasonal newsletter.

o The clinical and scientific panel continued to support Anaphylaxis UK with a focus on developing podcasts for our 'Talk to the experts' programme and clinically reviewing factsheets.

o Professor John Warner was appointed Clinical and Scientific Ambassador.

Anaphylaxis UK

Report of the Trustees for the Year Ended 31 December 2022

Patient Information

- o We achieved re-accreditation for our patient information factsheets from the Patient Information Forum (PIF) Tick quality mark in October 2022.
- o We commenced an extensive review and redevelopment of our entire library of factsheets to align with our new updated website and brand guidelines.
- o Following the launch of the new website in July 2022, we completely reviewed and updated all information resources.
- o We responded to over 2,000 helpline enquiries.

Communications

- o We launched our new Anaphylaxis UK YouTube Channel, which includes our podcast series "Talking to the expert" where we speak to medical experts such as Dr Helen Evan-Howells, Professor Adam Fox and Dr Graham Roberts.
- o We managed 36 press enquiries and our work was featured in national and local press, including iNews, The Guardian, The Times and BBC Breakfast.
- o We launched our new Anaphylaxis UK website in July 2022, which also merged with our AllergyWise website making sure that all of our training resources are in one place.
- o We received over 900,000 pageviews and over 500,000 users on our website.

Social media

- o Facebook followers grew to 17,772
- o Twitter followers grew to 10,156
- o Instagram followers grew 5,994
- o LinkedIn followers grew to 1,465
- o YouTube views were over 34,000

Newsletters

- o We moved to a new MailChimp platform for all our newsletter mailings in 2022.
- o Allergy Outlook newsletter grew to 4,691 subscribers with an average open rate of 62%.
- o Chief Executive newsletter grew to 1,974 subscribers with an average open rate of 62%
- o Healthcare professional newsletter become open to all healthcare professionals and grew to 958 subscribers with an average open rate of 48.8%.
- o Business newsletter to business members gained an average open rate of 25.5%.

Fundraising Highlights

- o Over £20,000 was raised by our TCS London Marathon 2022 and London Landmarks Half Marathon 2022 runners

Anaphylaxis UK

Report of the Trustees for the Year Ended 31 December 2022

- o A '5k a day in January' challenge was completed by one fundraiser, raising over £9,500 in memory of his friend
- o Nearly £5,000 raised from group challenges, including participation in the Jurassic Coast trek and London to Brighton cycle ride
- o The Christmas Appeal 2022 generated over £3,000 in individual donations; our most successful festive cash appeal ever!

Fundraiser Focus: In Memory of Michael

Friends of Michael, who died in July 2020 from anaphylaxis aged 23, first fundraised for Anaphylaxis UK in summer 2021 to honour his memory and first year anniversary. Their enthusiasm and commitment to raise funds and awareness continued in 2022. Friends completed a "5k a day" challenge in January 2022, and our charity was nominated for the annual Ulster University Magee Hurling match between the current team and Alumni members. In 2022, loved ones raised £13,300 for Michael and the grand total to date is £16,700.

Fundraiser Focus: London Marathon runner, Natalie

Natalie was one of our London Marathon runners for 2022 and is mum to 10 year old Max, who has several severe allergies. Natalie went above and beyond with her fundraising efforts. Along with generous donations on the JustGiving fundraising page, Natalie also organised a fun and successful Horse Racing Night raising over £2,800, including £700 from a raffle with prizes sourced from local businesses that Natalie approached. In total, Natalie raised £4,146!

Fundraiser Focus: Group Challenges

Introduced to our Challenge Event portfolio in Q3 2021, successful promotion of new team fundraising challenges saw several groups of friends and family participate in 2022. One team of friends climbed the steep hills of the Jurassic Coast in Dorset and raised £1,500. Another group trekked Snowdon by Night and raised nearly £1,200. And husband and wife, Ben and Melanie, cycled London to Paris and raised £1,500.

"We chose Anaphylaxis UK as our daughter has a severe allergy to peanuts and has had a near fatal reaction in the past. It was something we had a very limited knowledge of before the reaction, and we wanted to help a charity that raises awareness to make a difference.

"The London to Paris Cycle Ride was fantastic! We made sure we prepared in advance with sufficient training, and enjoyed the experience of seeing the different parts of France and getting to know and listen to other people's stories. The cycling and social element was great, we could have happily carried on for a few more days!"

Investment performance achieved against investment objectives

The investment objectives of the Charity are to maximise the value of reserves, while avoiding undue risk. The Charity's policy on investment includes a requirement to limit investments to 60% of liquid assets and only to invest in Funds regulated by the Financial Conduct Authority. The Charity's investments in an Income and Growth portfolio with Hargreaves Lansdown showed a loss of £8,078 on the value report at the end of December 2021 (£162,901). The value at the end of December 2022 was £154,824.

Financial review: Reserves policy

To achieve a sound balance between prudence and ensuring funds are expended in achieving the objectives of the Charity, the Trustees have established a policy whereby the unrestricted reserves held by the Charity should equate to at least six months operating costs. At the year end this equated to £231,589. Free reserves (excluding 6 months operating costs) at 31 December 2022 stood at £382,059.

Restricted reserves

Details of restricted funds are shown in note 16 of the financial statements.

Risk review

The Trustees have conducted a review of the major risks to which the Charity is exposed and systems have been established to manage those risks. A risk management register is maintained and risks highlighted are reviewed regularly to ensure they do not pose a threat to the Charity going forward. Key risks for the Charity include potential for loss of expertise and/or revenue from donations and fundraising activities.

Financial overview

The Charity ended the year in a sound financial position with sufficient free reserves to meet its reserves policy. Net outgoing resources for the year amounted to £529,537. Unrestricted funds were £613,648 and restricted funds were zero.

Financial policies

All payments up to £10,000 made by the Charity have to be signed by two authorised signatories and by a Trustee in addition for payments over that amount. The day-to-day management of the financial affairs of the Charity is delegated to the Head of Finance and Operations who submits Management Accounts and a written report monthly to the CEO and Board of Trustees. A financial report supported by Management Accounts is delivered at each meeting of Trustees.

Principal funding sources

The principal funding sources for the Charity are donations from a variety of individuals and Gift Aid. The Charity operates a very successful and comprehensive online training program for Schools, Early Years providers, Healthcare Professionals and Care Workers. The Charity also seeks funds from companies, charitable trusts and other sources to fund running costs and specific projects.

Use of funds

The funds received by the Charity during the year have helped to finance our Helpline and Information services, our reach to people with severe allergies, our research programs and our training programs.

PLANS FOR THE FUTURE

The Board have agreed a Business Plan that outlines the strategic direction for the charity over the next 5 years. for 2023-2028. The general impact the Anaphylaxis UK charity aims to achieve by the end of 2028 is:

Our ambition is for everyone with a serious allergy to enjoy the same quality of life as someone without an allergy. Over the next five years, all of our work will focus on making this ambition a reality.

Our main priority areas and the impact we aim to achieve within each area are set out in the Business Plan approved by the Board in March 2023. The main areas for future work will be:

- o **Information and Online Training:** We will provide the best information and online training in the UK about anaphylaxis for the public, public bodies and businesses.

o **Shared learning and best practices:** Leading valuable learning networks and forums across a broad spectrum of businesses in the food, medical device and pharmaceutical industries. Anaphylaxis UK is uniquely placed to promote greater collaboration, shared learning and facilitate dialogue between science and healthcare professionals, academia and public bodies. The Business Forum for our Business Members is leading the way in improving practice across the food and beverage industry and we are looking to replicate something similar for schools and allergy clinics.

o **Develop new and innovative digital resources and mediums:** New and emerging technologies and means of communication will offer opportunities to offer novel ways to share our services, reach more people, and support them more effectively. We are exploring new and exciting ways to share trusted information with a larger audience of beneficiaries and enhancing the way can work more efficiently.

o **Emotional and Psychological Support:** We will offer emotional and psychological support for people to feel less anxious about living with a serious allergy. We will develop a programme to support the emotional wellbeing of our benefactors by introducing a new service with trained therapists.

o **Access to Treatment:** We will ensure more people have access to the quality care they need to live with a serious allergy. We will influence the government and industry to improve the uptake of new innovations within the NHS and we will work with healthcare professionals to help them better understand the needs of people living with a serious allergy at risk of anaphylaxis.

o **Research:** We will offer opportunities to take part in research and clinical trials and our benefactors will learn what research is available.

o **Anaphylaxis Registry:** Supporting the adoption of a prospective UK Anaphylaxis Registry to provide a single place where episodes can be recorded to help research, understanding, and known prevalence.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

04133242 (England and Wales)

Registered Charity number

1085527

Registered office

1 Alexandra Road
Farnborough
GU14 6BU

Trustees

Dr A M Walker-Fraser Chair
Mr P M Littleton Vice Chair
Mr C Meads
Mrs T Randhawa
Mrs L C Wilkinson
Mrs S C Hall
Dr H E Evans-Howells
Mr R J Wright KC
Mr B Gaventa (resigned 10.3.23)

Company Secretary

Mrs L A Ingram

REFERENCE AND ADMINISTRATIVE DETAILS

Auditors

Chamberlains Statutory Auditors
and Chartered Accountants
Elm House, Tanshire Park
Shackleford Road, Elstead
Godalming
Surrey
GU8 6LB

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees (who are also the directors of Anaphylaxis UK for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditors are unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

AUDITORS

The auditors, Chamberlains Statutory Auditors, will be proposed for re-appointment at the forthcoming Annual General Meeting.

Approved by order of the board of trustees on 12 June 2023 and signed on its behalf by:

Dr A M Walker-Fraser - Trustee

Opinion

We have audited the financial statements of Anaphylaxis UK (the 'charitable company') for the year ended 31 December 2022 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2022 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to take advantage of the small companies exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Trustees.

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. This work includes discussion with management and Trustees, review of the minutes of Board Meetings. It also includes using analytical procedures to identify any unusual or unexpected matters and testing, on a sample basis, income and expenditure, including payroll. The extent to which our procedures are capable of detecting irregularities, including fraud, is considered to be reasonable in view of our audit work and the evidence obtained as described above.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Report of the Independent Auditors to the Members of
Anaphylaxis UK

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Paul J Chamberlain (Senior Statutory Auditor)
for and on behalf of Chamberlains Statutory Auditors
and Chartered Accountants
Elm House, Tanshire Park
Shackleford Road, Elstead
Godalming
Surrey
GU8 6LB

12 June 2023

Anaphylaxis UK

Statement of Financial Activities
for the Year Ended 31 December 2022

	Notes	Unrestricted fund £	Restricted funds £	31.12.22 Total funds £	31.12.21 Total funds £
INCOME FROM					
Donations and legacies	2	354,712	-	354,712	330,003
Charitable activities	5				
Sale of educational products		68,116	-	68,116	41,798
Product recall income		42,902	-	42,902	41,004
Other trading activities	3	73,134	-	73,134	109,133
Investment income	4	2,030	-	2,030	884
Total		<u>540,894</u>	<u>-</u>	<u>540,894</u>	<u>522,822</u>
EXPENDITURE ON					
Raising funds	6	76,821	-	76,821	83,195
Charitable activities	7				
Charitable activities		418,226	3,143	421,369	375,703
Other		31,347	-	31,347	21,140
Total		<u>526,394</u>	<u>3,143</u>	<u>529,537</u>	<u>480,038</u>
Net gains/(losses) on investments		<u>(8,078)</u>	<u>-</u>	<u>(8,078)</u>	<u>6,751</u>
NET INCOME/(EXPENDITURE)		6,422	(3,143)	3,279	49,535
RECONCILIATION OF FUNDS					
Total funds brought forward		607,226	3,143	610,369	560,834
TOTAL FUNDS CARRIED FORWARD		<u><u>613,648</u></u>	<u><u>-</u></u>	<u><u>613,648</u></u>	<u><u>610,369</u></u>

The notes form part of these financial statements

Anaphylaxis UK

Balance Sheet
31 December 2022

	Notes	Unrestricted fund £	Restricted funds £	31.12.22 Total funds £	31.12.21 Total funds £
FIXED ASSETS					
Intangible assets	13	38,496	-	38,496	7,343
Tangible assets	14	19,722	-	19,722	17,271
Investments	15	154,824	-	154,824	162,901
		<u>213,042</u>	<u>-</u>	<u>213,042</u>	<u>187,515</u>
CURRENT ASSETS					
Stocks	16	828	-	828	3,207
Debtors	17	70,689	-	70,689	57,138
Cash at bank and in hand		373,041	-	373,041	400,611
		<u>444,558</u>	<u>-</u>	<u>444,558</u>	<u>460,956</u>
CREDITORS					
Amounts falling due within one year	18	(43,952)	-	(43,952)	(38,102)
		<u>400,606</u>	<u>-</u>	<u>400,606</u>	<u>422,854</u>
NET CURRENT ASSETS					
		<u>400,606</u>	<u>-</u>	<u>400,606</u>	<u>422,854</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>613,648</u>	<u>-</u>	<u>613,648</u>	<u>610,369</u>
NET ASSETS		<u>613,648</u>	<u>-</u>	<u>613,648</u>	<u>610,369</u>
FUNDS	19				
Unrestricted funds				613,648	607,226
Restricted funds				-	3,143
TOTAL FUNDS				<u>613,648</u>	<u>610,369</u>

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 12 June 2023 and were signed on its behalf by:

Dr A M Walker-Fraser - Trustee

Anaphylaxis UK

Cash Flow Statement
for the Year Ended 31 December 2022

	Notes	31.12.22 £	31.12.21 £
Cash flows from operating activities			
Cash generated from operations	1	19,714	62,219
Net cash provided by operating activities		<u>19,714</u>	<u>62,219</u>
Cash flows from investing activities			
Purchase of intangible fixed assets		(39,670)	(13,241)
Purchase of tangible fixed assets		(14,909)	(6,613)
Sale of tangible fixed assets		5,265	-
Interest received		2,030	884
Net cash used in investing activities		<u>(47,284)</u>	<u>(18,970)</u>
Change in cash and cash equivalents in the reporting period		<u>(27,570)</u>	<u>43,249</u>
Cash and cash equivalents at the beginning of the reporting period		<u>400,611</u>	<u>357,362</u>
Cash and cash equivalents at the end of the reporting period		<u><u>373,041</u></u>	<u><u>400,611</u></u>

The notes form part of these financial statements

Notes to the Cash Flow Statement
for the Year Ended 31 December 2022

1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

	31.12.22	31.12.21
	£	£
Net income for the reporting period (as per the Statement of Financial Activities)	3,279	49,535
Adjustments for:		
Depreciation charges	15,710	10,663
Losses/(gain) on investments	8,078	(6,751)
Interest received	(2,030)	(884)
Decrease/(increase) in stocks	2,379	(1,030)
(Increase)/decrease in debtors	(13,551)	6,913
Increase in creditors	5,849	3,773
Net cash provided by operations	<u>19,714</u>	<u>62,219</u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.22	Cash flow	At 31.12.22
	£	£	£
Net cash			
Cash at bank and in hand	400,611	(27,570)	373,041
	<u>400,611</u>	<u>(27,570)</u>	<u>373,041</u>
Total	<u>400,611</u>	<u>(27,570)</u>	<u>373,041</u>

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery - 25% on cost

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease.

Investments

Fixed asset investments are treated as a single asset, revalued each year to current market value.

Notes to the Financial Statements - continued
for the Year Ended 31 December 2022

2. DONATIONS AND LEGACIES

	31.12.22	31.12.21
	£	£
Donations - members	29,595	31,685
Memoriam donations	30,151	44,201
Gift aid	37,906	23,555
Community fundraising & events	23,386	44,202
Charitable trusts and major donors	38,600	40,900
Corporate donations	8,825	3,406
Legacies	13,986	443
Individual membership	47,433	55,166
Professional membership	3,096	5,343
Corporate membership	57,955	58,890
Other including Google Adwords	63,779	22,212
	<u>354,712</u>	<u>330,003</u>

3. OTHER TRADING ACTIVITIES

	31.12.22	31.12.21
	£	£
Shop income	909	4,183
Event income	16,441	10,609
Advertising	-	240
Special project income	43,700	68,800
Other sundry income	8,784	8,101
Corporate sponsorship	3,300	17,200
	<u>73,134</u>	<u>109,133</u>

4. INVESTMENT INCOME

	31.12.22	31.12.21
	£	£
Dividends and interest rec'd	<u>2,030</u>	<u>884</u>

5. INCOME FROM CHARITABLE ACTIVITIES

The split of income from charitable activities is shown in the Statement of Financial Activities.

Notes to the Financial Statements - continued
for the Year Ended 31 December 2022

6. RAISING FUNDS

Raising donations and legacies

	31.12.22	31.12.21
	£	£
Staff costs	24,224	31,713
Other fundraising costs	9,457	9,241
Support costs	43,140	42,241
	<u>76,821</u>	<u>83,195</u>

7. CHARITABLE ACTIVITIES COSTS

	Direct Costs £	Support costs (see note 8) £	Totals £
Charitable activities	302,893	118,476	421,369
	<u>302,893</u>	<u>118,476</u>	<u>421,369</u>

8. SUPPORT COSTS

	General costs £	Governance costs £	Totals £
Raising donations and legacies	43,140	-	43,140
Other resources expended	-	31,347	31,347
Charitable activities	118,476	-	118,476
	<u>161,616</u>	<u>31,347</u>	<u>192,963</u>

9. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	31.12.22	31.12.21
	£	£
Audit fee	5,150	5,150
Auditor's remuneration for other work	750	900
Depreciation - owned assets	7,193	4,750
Hire of plant and machinery	8,775	31,550
Other operating leases	34,723	28,067
Computer software amortisation	8,517	5,898
	<u>76,821</u>	<u>83,195</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2022

10. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2022 nor for the year ended 31 December 2021.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 December 2022 nor for the year ended 31 December 2021.

11. STAFF COSTS

	31.12.22	31.12.21
	£	£
Wages and salaries	286,898	286,659
	<u>286,898</u>	<u>286,659</u>

The average monthly number of employees during the year was as follows:

	31.12.22	31.12.21
Fundraising	2	3
Charitable activities	6	9
	<u>8</u>	<u>12</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	31.12.22	31.12.21
£60,001 - £70,000	1	-
	<u>1</u>	<u>-</u>

12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted funds £	Total funds £
INCOME FROM			
Donations and legacies	330,003	-	330,003
Charitable activities			
Sale of educational products	41,798	-	41,798
Product recall income	41,004	-	41,004
Other trading activities	109,133	-	109,133
Investment income	884	-	884
Total	<u>522,822</u>	<u>-</u>	<u>522,822</u>
EXPENDITURE ON			
Raising funds	83,195	-	83,195
Charitable activities			
Charitable activities	371,350	4,353	375,703
Other	21,140	-	21,140
Total	<u>475,685</u>	<u>4,353</u>	<u>480,038</u>

12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued

	Unrestricted fund £	Restricted funds £	Total funds £
	<u> </u>	<u> </u>	<u> </u>
Net gains on investments	6,751	-	6,751
NET INCOME/(EXPENDITURE)	53,888	(4,353)	49,535
RECONCILIATION OF FUNDS			
Total funds brought forward	553,338	7,496	560,834
	<u> </u>	<u> </u>	<u> </u>
TOTAL FUNDS CARRIED FORWARD	<u>607,226</u>	<u>3,143</u>	<u>610,369</u>

13. INTANGIBLE FIXED ASSETS

	Computer software £
COST	
At 1 January 2022	13,241
Additions	39,670
	<u> </u>
At 31 December 2022	52,911
AMORTISATION	
At 1 January 2022	5,898
Charge for year	8,517
	<u> </u>
At 31 December 2022	14,415
NET BOOK VALUE	
At 31 December 2022	38,496
	<u> </u>
At 31 December 2021	7,343
	<u> </u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2022

14. TANGIBLE FIXED ASSETS

	Plant and machinery £
COST	
At 1 January 2022	66,544
Additions	14,909
Disposals	(37,603)
	<hr/>
At 31 December 2022	43,850
	<hr/>
DEPRECIATION	
At 1 January 2022	49,273
Charge for year	7,193
Eliminated on disposal	(32,338)
	<hr/>
At 31 December 2022	24,128
	<hr/>
NET BOOK VALUE	
At 31 December 2022	19,722
	<hr/> <hr/>
At 31 December 2021	17,271
	<hr/> <hr/>

15. FIXED ASSET INVESTMENTS

	Listed investments £
MARKET VALUE	
At 1 January 2022	162,901
Revaluations	(8,077)
	<hr/>
At 31 December 2022	154,824
	<hr/>
NET BOOK VALUE	
At 31 December 2022	154,824
	<hr/> <hr/>
At 31 December 2021	162,901
	<hr/> <hr/>

There were no investment assets outside the UK.

Fixed asset investments are revalued each year by the external fund managers.

16. STOCKS

	31.12.22	31.12.21
	£	£
Finished goods	828	3,207
	<hr/> <hr/>	<hr/> <hr/>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2022

17. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.12.22	31.12.21
	£	£
Trade debtors	23,449	7,481
VAT	2,190	8,405
Prepayments and accrued income	36,903	33,034
Accruals	8,147	8,218
	<u>70,689</u>	<u>57,138</u>

18. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.12.22	31.12.21
	£	£
Trade creditors	29,564	21,040
Social security and other taxes	5,078	7,421
Accruals and deferred income	2,469	2,822
Accrued expenses	6,841	6,819
	<u>43,952</u>	<u>38,102</u>

19. MOVEMENT IN FUNDS

	At 1.1.22	Net movement in funds	At 31.12.22
	£	£	£
Unrestricted funds			
General fund	607,226	6,422	613,648
Restricted funds			
Isle of Man Fund	3,143	(3,143)	-
TOTAL FUNDS	<u>610,369</u>	<u>3,279</u>	<u>613,648</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Gains and losses	Movement in funds
	£	£	£	£
Unrestricted funds				
General fund	540,894	(526,394)	(8,078)	6,422
Restricted funds				
Isle of Man Fund	-	(3,143)	-	(3,143)
TOTAL FUNDS	<u>540,894</u>	<u>(529,537)</u>	<u>(8,078)</u>	<u>3,279</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2022

19. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.21 £	Net movement in funds £	At 31.12.21 £
Unrestricted funds			
General fund	553,338	53,888	607,226
Restricted funds			
Isle of Man Fund	6,293	(3,150)	3,143
FSA Research Project	300	(300)	-
Survey, Review and Report	903	(903)	-
	<u>7,496</u>	<u>(4,353)</u>	<u>3,143</u>
TOTAL FUNDS	<u>560,834</u>	<u>49,535</u>	<u>610,369</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	522,822	(475,685)	6,751	53,888
Restricted funds				
Isle of Man Fund	-	(3,150)	-	(3,150)
FSA Research Project	-	(300)	-	(300)
Survey, Review and Report	-	(903)	-	(903)
	<u>-</u>	<u>(4,353)</u>	<u>-</u>	<u>(4,353)</u>
TOTAL FUNDS	<u>522,822</u>	<u>(480,038)</u>	<u>6,751</u>	<u>49,535</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.1.21 £	Net movement in funds £	At 31.12.22 £
Unrestricted funds			
General fund	553,338	60,310	613,648
Restricted funds			
Isle of Man Fund	6,293	(6,293)	-
FSA Research Project	300	(300)	-
Survey, Review and Report	903	(903)	-
	<u>7,496</u>	<u>(7,496)</u>	<u>-</u>
TOTAL FUNDS	<u>560,834</u>	<u>52,814</u>	<u>613,648</u>

Notes to the Financial Statements - continued
for the Year Ended 31 December 2022

19. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	1,063,716	(1,002,079)	(1,327)	60,310
Restricted funds				
Isle of Man Fund	-	(6,293)	-	(6,293)
FSA Research Project	-	(300)	-	(300)
Survey, Review and Report	-	(903)	-	(903)
	<u>-</u>	<u>(7,496)</u>	<u>-</u>	<u>(7,496)</u>
TOTAL FUNDS	<u>1,063,716</u>	<u>(1,009,575)</u>	<u>(1,327)</u>	<u>52,814</u>

20. RELATED PARTY DISCLOSURES

In October 2022 a subsidiary company, Anaphylaxis UK Trading Ltd, was formed. This subsidiary did not commence trading until 2023 and consequently there are no results to report as at 31 December 2022. Apart from the subscription for the whole of the £1 share capital of the subsidiary, there were no related party transactions.

Detailed Statement of Financial Activities
for the Year Ended 31 December 2022

	31.12.22 £	31.12.21 £
INCOME		
Donations and legacies		
Donations - members	29,595	31,685
Memoriam donations	30,151	44,201
Gift aid	37,906	23,555
Community fundraising & events	23,386	44,202
Charitable trusts and major donors	38,600	40,900
Corporate donations	8,825	3,406
Legacies	13,986	443
Individual membership	47,433	55,166
Professional membership	3,096	5,343
Corporate membership	57,955	58,890
Other including Google Adwords	63,779	22,212
	<hr/>	<hr/>
	354,712	330,003
Other trading activities		
Shop income	909	4,183
Event income	16,441	10,609
Advertising	-	240
Special project income	43,700	68,800
Other sundry income	8,784	8,101
Corporate sponsorship	3,300	17,200
	<hr/>	<hr/>
	73,134	109,133
Investment income		
Dividends and interest rec'd	2,030	884
Charitable activities		
Sale of educational products	68,116	41,798
Product recall income	42,902	41,004
	<hr/>	<hr/>
	111,018	82,802
Total incoming resources	<hr/>	<hr/>
	540,894	522,822
EXPENDITURE		
Raising donations and legacies		
Wages	24,224	31,713
Other fundraising costs	9,457	9,241
	<hr/>	<hr/>
	33,681	40,954
Charitable activities		
Wages	188,163	145,568
Shop and activity purchases	84,629	9,007
Carried forward	272,792	154,575

Anaphylaxis UK

Detailed Statement of Financial Activities
for the Year Ended 31 December 2022

	31.12.22	31.12.21
	£	£
Charitable activities		
Brought forward	272,792	154,575
Contractor costs	23,800	32,539
Conference and events	694	540
Special projects	5,607	95
	<hr/>	<hr/>
	302,893	187,749
Support costs		
General costs		
Wages	49,397	94,621
Rent and rates	8,775	31,550
Computer and software costs	34,723	28,067
Telephone	5,412	4,243
Travel and subsistence	2,072	1,532
Recruitment and redundancy	757	14,785
Staff training	2,074	2,713
Office expenses	2,625	1,447
Stationery and printing	102	1,079
Postage and carriage	2,160	3,840
Professional fees	4,678	14,156
Website costs	3,189	6,091
Insurance	2,350	2,525
Irrecoverable VAT	15,447	6,687
Sundry	6,904	944
Bank charges	5,241	5,252
Plant and machinery	15,710	10,663
	<hr/>	<hr/>
	161,616	230,195
Governance costs		
Wages	25,114	14,757
Auditors' remuneration	5,900	6,050
Sundries	333	333
	<hr/>	<hr/>
	31,347	21,140
Total resources expended	<hr/>	<hr/>
	529,537	480,038
Net income	<hr/>	<hr/>
	11,357	42,784


This page does not form part of the statutory financial statements

ANAPHYLAXIS UK

England & Wales - Charity number 1085527

Accounts

Anaphylaxis Campaign (incorporating the Latex Allergy Support Group)



**Anaphylaxis Campaign (incorporating the Latex Allergy Support Group)
(Limited by Guarantee)**

Trustees Report and Financial Statements

Registered Charity Number: 1085527

Company Number: 04133242

Anaphylaxis Campaign (incorporating the Latex Allergy Support Group)

Contents	Page
Trustees' Report	4 - 10
Auditors' Report	11 – 13
Statement of Financial Activities	14
Balance Sheet	15
Statement of Cash Flows	16
Notes to the Accounts	17 – 27

Trustees' Report

Legal and Administrative Information

Year ended 31 December 2021

Reference and administration details of the charity, its Trustees and advisors

Company Number: 04133242

Charity Number: 1085527

Patrons

Mark Foster
Giorgio Locatelli
Jo Frost

Hon. President

David Reading OBE

Trustees

Trustees who are directors for the purpose of company law and trustees for the purpose of charity law, who served during the year, are as follows:

Mrs Sarah Lassman	Chair – Retired October 2021
Ms Alison Skinner	Hon.Treasurer – Resigned April 2021
Dr Alison Walker-Fraser	Chair – Appointed October 2021
Dr Joanne Walsh	Resigned – October 2021
Mr Boaz Gaventa	
Mr Chris Meads	
Mrs Louise Wilkinson	
Mrs Taj Randhawa	
Mr Peter Littleton	Vice Chair – Appointed October 2021
Mrs Susan Hall	Hon.Treasurer Appointed – August 2021
Dr Helen Evans-Howells	Appointed – November 2021
Mr Richard Wright QC	Appointed – November 2021

Chief Executive of Anaphylaxis Campaign

Mrs J. L. Regent – Retired August 2021
Mr Simon Williams – Appointed November 2021

Registered office

1 Alexandra Road
Farnborough
Hampshire GU14 6BU

Operational Office

1 Alexandra Road
Farnborough
Hampshire GU14 6BU

Website: www.anaphylaxis.org.uk

Trustees' Report

Legal and Administrative Information (*continued*)

Year ended 31 December 2021

Reference and administration details of the charity, its Trustees and advisors

Bankers

HSBC Bank plc
54 High Street
Epsom
Surrey KT19 8DS

Investment Advisors

Hargreaves Lansdown
One College Square South
Anchor Road
Bristol BS1 5HL

Solicitors

Stone King LLP
Boundary Street
91 Charterhouse Street
London EC1M 6HR

Independent Auditor

Chamberlains
Elm House
Shackleford Road
Elstead GU8 6LB

The Trustees, who are also the Directors of the Charity for the purposes of the Companies Act, are pleased to present their report, together with the financial statements for the Year ended 31 December 2021.

2021 – Achievements and Performance

Schools and Universities

- We launched our new model policy for management of allergy at school at the BSACI Annual Conference in October 2021.
- We launched our new Education Ambassador, head teacher Tracey Dunn during Allergy Awareness Week.
- We continued to promote the legislation which enables schools in England and Wales, from September 2017, to hold a spare adrenaline auto-injector in case of emergency. In addition, we continued to support the www.sparepensinschools.uk website. This message was reinforced in 2021 through two mailings to 27,000 schools with an average open rate of 12%.
- We promoted the Anaphylaxis Campaign to all UK universities through a mailing. This had an opening rate of 21%. We presented at the Association for Student Residential Accommodation (ASRA) northern regional meeting with Melissa Singh. We published an article in The University Caterers Organisation (TUCO) Newsletter.

Working with healthcare and allergy services

- We continued our joint work with BSACI and Allergy UK to update our Covid 19 Hub and frequently asked Covid 19 vaccination questions to support both healthcare professionals and patients.
- We developed a campaign to support hospitals undertake safe discharges of severely allergic patients, based on NICE Anaphylaxis Clinical Guidelines which was launched on the Isle of Mann during Allergy Awareness Week.
- We sat as patient experts on the NICE technology appraisal committee for Palforzia, a novel immunotherapy treatment for peanut allergy which was later approved for NHS use in children aged 4-17 years.
- Our Corporate Panel and our Clinical and Scientific Panel were both active throughout the year providing relevant advice to support our work.

Communication

- We staged 7 webinars, with opportunities for questions, attended by over 600 people including a webinar by our new Education Ambassador, Tracey Dunn 'Making Schools Safer – Allergy in the Curriculum'.
- We responded to over 4,000 helpline enquiries by email, telephone and social media.
- We managed over 45 press enquiries and our work was featured in national and local press, including the BBC News, ITV This Morning, iNews, Public Sector Catering and Fundraising UK.
- We received over 1,585,000 visits to our Anaphylaxis Campaign website and over 70,000 to our AllergyWise website.
- In September 2021 we launched our new AllergyWise website on the Teachable platform
- We worked with the Co-op to produce a suite of allergy awareness training resources for use in their academies.
- We attended the Allergy and FreeFrom Show in Birmingham where we gave advice to over 130 families.

Social Media

- Facebook followers grew to 16,907
- Twitter followers grew to 9,842
- Instagram followers grew to 4,894
- LinkedIn followers grew to 1,158
- YouTube views were over 40,000

Volunteers and Support Groups

- We held 9 Virtual Support Groups.
- 15 lay reviewer volunteers looked at and reviewed our fact sheets.
- 3 office/work from home volunteers assisted in building databases.
- Over 25 people needing our support were matched with allergy buddies.

Fundraising highlights

- Gulliver Kocher cut his hair in memory of his uncle, Owen Carey raising over £2,500
- Oliver Bennett completed a 24-hour trampoline-athon raising £1,200
- Our London Marathon and London Landmarks Half Marathon runners raised over £30,000
- Our Allergy Awareness Week Fundraisers who took on 140,000 steps in 14 days raised over £4,000
- Christmas cards – We raised £3,661

Company Information

Anaphylaxis Campaign (incorporating the Latex Allergy Support Group) (the 'Campaign') was incorporated under the Companies Act on 29 December 2000 and is a company limited by guarantee. The Campaign was registered as a charity on 13 March 2001 and its governing document is a Memorandum of Association dated 31 July 2021. The Campaign is also recognised by HM Revenue & Customs as a charity for tax purposes.

Structure, Governance and Management

The Campaign's Memorandum of Association sets out the objects and powers of the charitable company and is governed under its Articles of Association. Under those Articles, one third of the Trustees retire each year and Trustees are appointed at the first Trustee meeting in each financial year to serve for a period of approximately three years.

Trustees are recruited to ensure a balanced board with a mix of skills. All new Trustees are given an induction which includes learning about the background, ethos and day to day activities of the Campaign as well as outlining their responsibilities. The maximum number of Trustees allowed by the Campaign's governing document is eleven and at 31 December 2021 there were nine.

The Governance structure is made up of a Board of Trustees. The Chief Executive is not a Trustee but a permanent non-voting member of the Board, with the right to attend all Board meetings unless a conflict of interest exists. The Business Manager for the Campaign is also its Company Secretary. Other members of staff from the Campaign attend as required.

The Board usually meets quarterly and holds an annual Strategy Day in addition, which all Trustees and the Chief Executive are expected to attend. Trustees may also attend any of the Campaign's conferences and events relevant to their particular roles during the year.

The Campaign operates in a consistent way by following the policies set out and agreed by the Board, supported and implemented by the Chief Executive and supporting staff. Day to day responsibility rests with the Chief Executive, who is responsible for all staff.

Investment performance achieved against investment objectives

The investment objectives of the Campaign are to maximise the value of reserves, while avoiding undue risk. The Campaign's policy on investment includes a requirement to limit investments to 60% of liquid assets and only to invest in Funds regulated by the Financial Conduct Authority. The Campaign's investments in an Income and Growth portfolio with Hargreaves Lansdown showed a gain of £6,751 on the value report at the end of December 2020 (£156,150). The value at the end of December 2021 was £162,901.

Financial review Reserves policy

To achieve a sound balance between prudence and ensuring funds are expended in achieving the objectives of the Campaign, the Trustees have established a policy whereby the unrestricted reserves held by the Campaign should equate to at least six months operating cost. At the year end this equated to £240,019. Free reserves (excluding 6 months operating costs) at 31 December 2021 stood at £367,207.

Restricted reserves

Details of restricted funds are shown in note 16 of the financial statements.

Risk review

The Trustees have conducted a review of the major risks to which the Campaign is exposed and systems have been established to manage those risks. A risk management register is maintained and risks highlighted are reviewed regularly to ensure they do not pose a threat to the Campaign going forward. Key risks for the Campaign include potential for loss of expertise and/or revenue from donations and fundraising activities. All Trustees received regular governance training.

Statement of Trustees' responsibilities

The trustees (who are also directors of the Campaign for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Auditor

Chamberlains were appointed auditors at the Annual General Meeting of the Campaign held on 5th July 2021.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

This report was approved by the Trustees on 28/4/22.....and signed on their behalf.



Dr Alison Walker-Fraser
Chair

Report of the Auditors to the Members of
The Anaphylaxis Campaign (Incorporating the Latex Allergy Support Group)

Opinion

We have audited the financial statements of The Anaphylaxis Campaign (Incorporating the Latex Allergy Support Group) (the 'charitable company') for the year ended 31 December 2021 which comprise the Income Statement, Balance Sheet and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The Trustees are responsible for the other information. The other information comprises the information in the Report of the Trustees, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Trustees.

Responsibilities of the Trustees

As explained more fully in the Statement of Trustees' Responsibilities set out on page five, the Trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or has no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is considered to be reasonable in view of our audit work and the evidence obtained as described above.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Report of the Auditors to the Members of
The Anaphylaxis Campaign (Incorporating the Latex Allergy Support Group)

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Paul Chamberlain (Senior Statutory Auditor)
for and on behalf of Chamberlains Statutory Auditors
and Chartered Accountants

Elm House, Tanshire Park
Shackleford Road, Elstead
Godalming
Surrey
GU8 6LB

Date: 12 May 2022

Part of
the company
is responsible
for the preparation
and maintenance

Part of
the company
is responsible
for the preparation
and maintenance

Part of
the company
is responsible
for the preparation
and maintenance

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Statement of financial activities (incorporating an income and expenditure account)

Year ended 31 December 2021

	Notes	Unrestricted funds £	Restricted Funds £	Total 2021 £	Unrestricted funds £	Restricted funds £	Total 2020 £
Income from:							
Donations	2	330,003	-	330,003	382,487	63,387	445,874
Other trading activities	2	109,133	-	109,133	77,668	-	77,668
Income from investments	3	884	-	884	1,582	-	1,582
Income from charitable activities	2	82,802	-	82,802	97,157	-	97,157
Total income		522,822	-	522,822	558,894	63,387	622,281
Expenditure on:							
Raising funds		40,954	-	40,954	28,188	-	28,188
Charitable activities		434,731	4,353	439,084	384,097	82,776	466,873
Total expenditure	4	475,685	4,353	480,038	412,285	82,776	495,061
Net gains/(losses) on investments	11	6,751	-	6,751	(6,941)	-	(6,941)
Net income/(expenditure)		53,888	(4,353)	49,535	139,668	(19,389)	120,279
Transfer between funds							
Net movement in Funds		-	-	-	28,756	(28,756)	-
		53,888	(4,353)	49,535	168,424	(48,145)	120,279
Reconciliation of funds:							
Total funds brought forward		553,338	7,496	560,834	384,914	55,641	440,555
Total funds carried forward	15 / 16	607,226	3,143	610,369	553,338	7,496	560,834

The Statement of financial activities includes all gains and losses in the year.

All income and expenditure derive from continuing activities.

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)


Balance Sheet

Year ended 31 December 2021

	Note	2021 £	2020 £
Fixed Assets			
Tangible assets	10	24,614	15,407
Investments	11	162,901	156,150
		<u>187,515</u>	<u>171,557</u>
Current assets			
Stock		3,207	2,193
Debtors	12	57,138	64,051
Cash at bank		400,611	357,362
		<u>460,956</u>	<u>423,606</u>
Creditors - amounts falling due within one year	13	(38,102)	(34,329)
Net current assets		422,854	389,277
Total assets less current liabilities		<u><u>610,369</u></u>	<u><u>560,834</u></u>
Funds			
Restricted funds	16	3,143	7,496
Unrestricted funds	15	607,226	553,338
Total funds		<u><u>610,369</u></u>	<u><u>560,834</u></u>

These financial statements have been prepared in accordance with the special provisions of Section 15 of the Companies Act 2006 relating to small companies.

Approved by the Trustees and authorised for issue on 28/4/2022 and signed on their behalf by:

 - Trustee

DR ALISON WALKER - FRASER

Company Registration Number: 04133242

The notes on pages 17 to 28 form part of these financial statements.

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Statement of Cash Flows

Year ended 31 December 2021

	Note	2021 £	2020 £
Cash flows from operating activities	20	62,220	134,291
Cash flows from investing activities			
Purchase of fixed assets		(19,854)	(1,497)
Interest received		884	1,582
Net cash flow from investing activities		(18,970)	85
Net increase/(decrease) in cash and cash equivalents		43,250	134,376
Cash and cash equivalents at beginning of year		357,361	222,985
Cash and cash equivalents at end of year		400,611	357,361

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements

Year ended 31 December 2021

1. Accounting policies

General information

The Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group) is a company limited by guarantee in the United Kingdom. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The address of the registered office is given in the charity information on page 2 of these financial statements. The nature of the charity's operations and principal activities are to: a) advance the education and general understanding of the public concerning life-threatening allergies and associated disorders; b) to protect the health of people who may be at risk of severe allergic reactions by providing help and information to them, their family and friends; and c) to promote research into the cause and care of severe allergic conditions and to publish the results of such research.

The charity constitutes a public benefit entity as defined by FRS102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) issued on 16 July 2014, the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102), the Companies Act 2006 and UK Generally Accepted Practice.

Basis of preparation

The financial statements have been prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value.

The financial statements are prepared in sterling and monetary amounts are rounded to the nearest £.

The significant accounting policies applied in the preparation of these financial statements are set out below.

These policies have been consistently applied to all years presented unless otherwise stated.

Tangible Fixed Assets

All fixed assets to a value of £500 or more are capitalised at cost. Depreciation is provided on all fixed assets at rates calculated to write off the cost of the asset over its expected useful life as follows:

Equipment: 25% straight line on cost.

Income recognition

All incoming resources are included in the Statement of Financial Activities (SoFA) when the charity is legally entitled to the income after performance conditions have been met, the amount can be measured reliably and it is probable that the income will be received.

Donations and subscriptions

Membership donations, memoriam donations, major donors, legacies and charitable trust income is recognised on a receipts basis.

Corporate donations, corporate membership and professional membership income is recognised on a receivable basis.

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2021

1. Accounting policies (continued)

Income recognition (continued)

Donations and subscriptions (continued)

Individual membership received by direct debit is recognised on a receivable basis. For those members who pay by cheque or credit card, recognition is on a received basis.

Gift Aid income includes the Gift Aid on all applicable donations received in the year under review.

Gifts in kind

Donated professional services are recognised in income at their fair value when their economic benefit is probable, it can be measured reliably and the Campaign has control over the item. Fair value is determined on the basis of the value of the gift to the charity. For example the amount the charity would be willing to pay in the open market for such services. A corresponding amount is recognised in expenditure.

Community fundraising

Income is recognised on a received basis.

Event income and corporate sponsorship

Income earned from fundraising and sponsored events is recognised on the date the event is held.

Sale of educational products

Income is received for the sale of online "AllergyWise" courses written by the Campaign. Income is recognised on a received basis.

Product recall income

Product recall income is income received from retailers for the Campaign, contacting their members about mislabelled products. The invoiced amount is based on the type of product mislabelled, the difference types of alerts sent and the membership status of the retailer. Income is recognised on a receivable basis net of VAT.

Investment income

Investment income is earned through holding assets for investment purposes, and includes dividends and interest. Where it is not practicable to identify investment management costs incurred within a scheme with reasonable accuracy the investment income is reported net of these costs. It is included when the amount can be measured reliably. Investment income is recognised on a received basis.

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2021

1. Accounting policies (continued)

Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate

Costs of raising funds: includes all direct fundraising costs, including costs of staff specifically engaged in community, trust and corporate fundraising.

Costs of charitable activities: includes all costs (including support costs) for the Campaign's activities in meeting our charitable objectives.

Governance costs: includes costs incurred in the governance of the charity and its assets, primarily associated with constitutional and statutory requirements.

Support costs allocation

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office expenses, governance costs, administrative payroll costs. They are incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters. Where support costs cannot be directly attributable to particular headings they have been allocated to cost of raising funds and expenditure on charitable activities on a basis consistent with use of the resources. Premises and other overheads have been allocated on an accruals basis.

Fund-raising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities.

The analysis of these costs is included in note 5.

Debtors

Trade and other debtors are recognised at the settlement amount due after any discounts offered to members. Prepayments are valued at the amount prepaid.

Cash at bank

Cash at bank includes cash and fixed term deposit accounts with a short term maturity of twelve months.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any discounts due.

Fund accounting

Unrestricted funds are available to spend on activities that further any of the purposes of the Campaign. Designated funds are unrestricted funds of the charity which the Trustees have decided at their discretion to set aside to use for a specific purpose. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the Campaign's work or for specific projects being undertaken by the Campaign.

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2021

1. Accounting policies (continued)

Leasing

Rentals payable under operating leases are charged against income on a straight line basis over the lease term.

Taxation

The charitable company's activities are exempt from taxation under Sections 466-493 of the Corporation Tax Act 2010.

Investments

The carrying value of the investment at the accounting date represents the fair value of the underlying quoted investments and deposits.

The net realised and unrealised gains and losses of the underlying investments are reflected through the statement of financial activities.

Pensions

The charity operates a defined contribution plan for the benefit of its employees. Contributions are expensed as they become payable.

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2021

2. Incoming resources

Donations	2021	2020
	£	£
Membership donations	31,685	30,595
Memoriam donations	44,201	7,340
Corporate donations	3,406	4,414
Charitable trust income & major donors	40,900	56,550
Legacies	443	103,966
Gift aid	23,555	18,814
Community fundraising	44,202	42,734
Individual membership	55,166	55,701
Professional membership	5,343	6,252
Corporate memberships	58,890	64,115
Other - including COVID support funding	22,212	55,393
	330,003	445,874

Included in legacies for 2020 are amounts of £102,965 from the estate of Penelope Sibson and £1,000 from the estate of Wendy Thomson. A further £433 has been received from the estate of Penelope Sibson in 2021.

Other trading activities	2021	2020
	£	£
Sale of goods	4,183	4,668
Advertising	240	720
Event income	10,609	-
Corporate sponsorship	17,200	-
Special project income	68,800	63,687
Other	8,101	8,593
	109,133	77,668

Charitable activities	2021	2020
	£	£
Sale of education products	41,798	36,932
Product recall income	41,004	60,225
	82,802	97,157

3. Income from investments	2020	2020
	£	£
Bank Interest	884	1,582

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2021

4. Total expenditure	Activities undertaken directly £	Support costs £	Total 2021 £	Total 2020 £
Raising funds	40,954	-	40,954	28,188
Charitable activities	187,749	230,195	417,944	440,560
Governance costs	-	21,140	21,140	26,313
Total	228,703	251,335	480,038	495,061

5. Allocation of support costs

	Basis of apportionment	Support costs £	Total 2021 £	Total 2020 £
Staff costs	Staff time	110,951	110,951	92,246
Office rental and other office costs	Invoiced events	73,919	73,919	70,853
Travel expenses	Non-governance expenses	1,532	1,532	1,554
Legal / Professional costs	Invoiced events	14,156	14,156	26,706
Finance expenses	Bank charges payable	5,252	5,252	5,195
Website costs	Software cost and usage	6,091	6,091	5,617
Depreciation	Estimated useful life	10,663	10,663	9,852
Other costs	Invoiced events	7,631	7,631	9,294
		230,195	230,195	221,317

6. Allocation of governance costs

	Activities undertaken directly £	Total 2021 £	Total 2020 £
Staff costs	14,757	14,757	19,085
Audit fees	6,050	6,050	5,750
Travel and subsistence expenses	333	333	1,478
	21,140	21,140	26,313

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2021

7. Staff

The average monthly number of employees and full time equivalent (FTE) during the year was as follows:

	2021 Number	2021 FTE	2020 Number	2020 FTE
Raising funds	3	2	3	2
Charitable activities	9	7	10	8
Governance	-	-	-	-
	<u>12</u>	<u>9</u>	<u>13</u>	<u>10</u>

The total staff costs and employees benefits was as follows:

	2021 £	2020 £
Staff costs		
Wages & salaries	262,903	277,830
Employers NI	18,630	17,208
Pension costs	5,126	4,865
	<u>286,659</u>	<u>299,903</u>

None of the Trustees was employed by the Campaign, or had any interest in any contracts with the Campaign in either year. During the year £378 in respect of travel was reimbursed to two Trustees for expenditure incurred on the Campaign's business (2020: £1,478 - three Trustees).

No employee was paid more than £60,000 in either 2021 or 2020.

The key management personnel of The Campaign is the Chief Executive Officer. Total employee benefits for the two individuals who held this position during the course of the year, including Employer National Insurance contributions, were £59,003 (2020: £53,796).

8. Net income / (expenditure) for the year

The net income / (expenditure) is stated after charging / (crediting):	2021 £	2020 £
Depreciation of tangible fixed assets	10,663	9,852
Operating lease rentals	<u>29,000</u>	<u>29,000</u>

9. Auditor's remuneration

The auditor's remuneration amounts to an audit fee of £5,150 (2020: £5,000)

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2021

10. Fixed assets

Cost	Equipment £
At 1 January 2021	86,119
Additions	19,854
Disposals	(26,188)
At 31 December 2021	<u>79,785</u>
Depreciation	
At 1 January 2021	70,711
Charge for the year	10,648
Disposals	(26,188)
At 31 December 2021	<u>55,171</u>
Net book value	
At 31 December 2021	<u>24,614</u>
At 31 December 2020	<u>15,407</u>

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2021

11. Investments

	2021 £	2020 £
Market value at 1 January	156,150	163,091
Additions	-	-
Disposals	-	-
Unrealised (loss)/gain on revaluation	6,751	(6,941)
Market value at 31 December	<u>162,901</u>	<u>156,150</u>

	2021		2020	
	Market value £	Cost £	Market value £	Cost £
Quoted investments				
UK - equities	161,113	132,963	155,115	132,963
Cash fund	1,788	1,788	1,035	1,035
	<u>162,901</u>	<u>134,751</u>	<u>156,150</u>	<u>133,998</u>

Included in the market value of investments at 31 December 2020 individual investments that are material to the investment portfolio valuation were:

	No. of ordinary shares / units	Market value	Cost at 31 December 2021	Percentage of total valuation
HL Multi-Manager Income & Growth Trust	68,559	£ 66,687	£ 52,923	40.9%
HL Multi-Manager Strategic Bond Trust	40,608	£ 61,013	£ 52,279	37.5%
HL Multi-High Income Trust	16,170	£ 17,511	£ 16,660	10.7%

The income shown above is after management fees.

12. Debtors

	2021 £	2020 £
Trade debtors	7,481	18,279
Prepayments	33,034	38,934
Accrued income	8,218	4,758
HMRC VAT liability (repayment)	8,405	2,080
	<u>57,138</u>	<u>64,051</u>

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2021

13. Creditors	2021	2020
	£	£
Trade creditors	21,040	3,723
Other taxation and social security	7,421	5,283
Accruals	6,819	8,691
Deferred income (see note 14)	2,822	16,632
	<u>38,102</u>	<u>34,329</u>
14. Deferred income	2021	2020
	£	£
Income received in advance	<u>2,822</u>	<u>16,632</u>
	2021	2020
	£	£
At 1 January 2019	16,632	8,880
Amount released to incoming resources	(16,632)	(8,880)
Amount deferred in the year	2,822	16,632
As at 31 December 2019	<u>2,822</u>	<u>16,632</u>
Income in support of 2021 activities was the following:		
Corporate Subscriptions	2,822	16,632
	<u>2,822</u>	<u>16,632</u>

Income has been deferred for the above sponsorship, donations and subscriptions as they relate to events which are due to take place in 2021.

15. Unrestricted funds

	At 1 January 2021	Incoming resources	Outgoing resources	Gain on investment	Transfer to/from unrestricted	At 31 December 2021
	£	£	£	£	£	£
General fund	553,338	522,822	(475,685)	6,751	-	607,226
	<u>553,338</u>	<u>522,822</u>	<u>(475,685)</u>	<u>6,751</u>	<u>-</u>	<u>607,226</u>

Name of unrestricted fund

General fund

Description, nature and purpose of the fund

The 'free reserves' after allowing for all designated funds.

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2021

16. Restricted funds

	At 1 January 2021 £	Incoming resources £	Outgoing resources £	Transfer to/from unrestricted £	At 31 December 2021 £
Isle of Man Fund	6,293		(3,150)		3,143
FSA Research Project	300		(300)		-
Survey, Review and Report	903		(903)		-
	7,496	-	(4,353)	-	3,143

17. Analysis of net assets between funds

	Unrestricted £	Restricted £	Total 2021 £	Total 2020 £
Fixed tangible assets	24,614	-	24,614	15,407
Fixed investment	162,901	-	162,901	156,150
Current assets	457,813	3,143	460,956	423,606
Current liabilities	(38,102)	-	(38,102)	(34,329)
	607,226	3,143	610,369	560,834

18. Operating leases

Future minimum payments under non-cancellable operating leases are £7,250 (2020: £3665,250).

19. Pensions

The charity operates a defined contribution pension plan for its employees. The amount recognised as an expense in the year was £5,126 (2020: £4,865) included within unrestricted charitable activities and support costs.

20. Reconciliation of Net Movement in Funds to Net Cash Flow from Operating Activities

	2021 £	2020 £
Net movement in funds	49,535	120,278
Add back depreciation	10,648	9,852
(Deduct)/add back (gains)/losses on investments	(6,751)	6,941
(Deduct) interest income	(884)	(1,582)
(Increase)/decrease in stock	(1,014)	355
(Increase)/decrease in debtors	6,913	9,591
Increase/(decrease) in creditors	3,773	(11,144)
Net cash generated in operating activities	62,220	134,291

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Detailed income and expenditure account

Year ended 31 December 2021

	2021		2020	
	£	£	£	£
Income				
Subscriptions		119,399		126,068
Donations - members		31,685		30,595
Donations - other		134,717		246,476
Product Alerts income		41,004		30,225
Advertising & Sponsorship		17,440		720
Sale Proceeds		45,981		41,600
Community fundraising & events		54,811		42,734
Special project income		68,800		63,687
Other sundry income		8,101		8,593
Bank interest		884		1,582
		<u>522,822</u>		<u>622,280</u>
Cost of sales (net of closing stock value)		<u>(4,293)</u>		<u>(2,798)</u>
		518,529		619,482
Expenditure				
Wages & salaries	286,659		299,903	
Subcontract consultants	32,539		27,141	
Communications, magazine, design	4,714		5,198	
Website	6,091		5,617	
Fundraising expenses	9,241		6,335	
Conferences & events	540		1,650	
Office expenses	1,447		1,881	
Rent & rates	31,550		31,541	
Light & heat	-		1,342	
Staff training	1,545		(84)	
Staff recruitment	14,785		-	
Telephone & internet	4,243		4,355	
Stationery & printing	881		1,117	
Postage & carriage	3,840		3,973	
Photocopying	198		320	
Travel, subsistence & accommodation	1,865		3,032	
Computer and software	28,067		23,917	
Insurance	2,525		2,407	
Bank charges	5,252		5,195	
Audit	6,050		5,750	
Professional fees	14,156		26,706	
Depreciation	10,663		9,852	
Subscriptions & journals	1,168		770	
Sundry	944		487	
Irrecoverable VAT	6,687		8,037	
Bad debts	-		-	
Special Projects & research grants	95		15,731	
Support Groups	-		90	
		<u>(475,745)</u>		<u>(492,263)</u>
Surplus for the year from operations		42,784		127,219
Gain/loss on investments		<u>6,751</u>		<u>(6,941)</u>
Total surplus for the year		<u>49,535</u>		<u>120,278</u>

ANAPHYLAXIS UK

England & Wales - Charity number 1085527

Accounts

Anaphylaxis Campaign (incorporating the Latex Allergy Support Group)



**Anaphylaxis Campaign (incorporating the Latex Allergy Support Group)
(Limited by Guarantee)**

Trustees Report and Financial Statements

Registered Charity Number: 1085527

Company Number: 04133242

Anaphylaxis Campaign (incorporating the Latex Allergy Support Group)

Contents	Page
Trustees' Report	1 - 11
Auditors' report	12 - 13
Statement of Financial Activities	14
Balance sheet	15
Statement of cash-flows	16
Notes to the Accounts	17 – 27

Trustees' Report

Legal and Administrative Information

Year ended 31 December 2020

Reference and administration details of the charity, its Trustees and advisors

Company Number: 04133242

Charity Number: 1085527

Patrons

Mark Foster
Giorgio Locatelli
Jo Frost

Hon. President

David Reading OBE

Trustees

Trustees who are directors for the purpose of company law and trustees for the purpose of charity law, who served during the year, are as follows:

Mrs Sarah Lassman	Chair
Ms Alison Skinner	Hon. Treasurer – Retired April 2021
Mrs Sue Clarke	Retired December 2020
Mr Boaz Gaventa	
Dr Alison Walker-Fraser	
Dr Joanne Walsh	
Mr Chris Meads	Appointed December 2020
Mrs Louise Wilkinson	Appointed December 2020
Mrs Taj Randhawa	Appointed December 2020
Mr Peter Littleton	Appointed December 2020

Chief Executive of Anaphylaxis Campaign

Mrs J. L. Regent

Registered office

1 Alexandra Road
Farnborough
Hampshire GU14 6BU

Operational Office

1 Alexandra Road
Farnborough
Hampshire GU14 6BU

Website: www.anaphylaxis.org.uk

Bankers

HSBC Bank plc

54 High Street
Epsom
Surrey KT19 8DS

Investment Advisors

Hargreaves Lansdown
One College Square South
Anchor Road
Bristol BS1 5HL

Solicitors

Stone King LLP
Boundary Street
91 Charterhouse Street
London EC1M 6HR

Independent Auditor

Chamberlains
Elm House
Shackleford Road
Elstead GU8 6LB

The Trustees, who are also the Directors of the Charity for the purposes of the Companies Act, are pleased to present their report, together with the financial statements for the Year ended 31 December 2020.

2020 – Our Impact

- We continued to engage with allergy clinics across the UK during 2020 to support them as they managed their clinics remotely during the Covid 19 pandemic. We provided links to our Covid 19 Hub with 'Frequently asked Questions' to help them support their patients.
- We continued to promote the legislation which enables schools in England and Wales, from September 2017, to hold a spare adrenaline auto-injector in case of emergency. In addition, we continued to support the www.sparepensinschools.uk website. This message was reinforced in 2020 through two mailings to 27,000 schools with an average open rate of 12%.
- Our Corporate Panel and our Clinical and Scientific Panel were both active throughout the year providing relevant advice to support our work.
- We took forward a programme of diversity training for all staff, trustees and for volunteers and collaborated with initiatives taken forward by clinical partners to address ethnic differences.
- We developed a toolkit of resources for GPs, pharmacists and practice nurses working in Primary Care to help them support their patients. We reached over 2,900 healthcare professionals.
- We continue to engage with legislators, regulators Local Authorities and individual food companies to improve food safety for the allergic population.
- We staged 7 webinars, with opportunities for questions, attended by 2,670 people including a webinar by Professor George Du Toit 'Managing your allergies in the time of Coronavirus'.
- We promoted the Anaphylaxis Campaign to all UK universities through a mailing. This had an opening rate of 17%. It included a new tops tips poster for starting university and promoted our Covid 19 hub. We shared our Youth Ambassador's podcast with tips for being an allergic student at university.
- We attended the Allergy Food Show in Glasgow where we gave advice to over 100 families.
- We responded to over 2,000 helpline enquiries by email, telephone and social media.
- Our work was featured in national and local press, including the BBC News, The Mirror, Sunday Post and New Food Magazine.
- 46,500 people undertook our AllergyWise courses in 2020 and this included over 42,000 completing the 'AllergyWise for Schools' course.
- Our fundraisers remained enthusiastic, committed and flexible during a challenging year. Many postponed planned events to a later date. Others completed challenges virtually, ensuring their fundraising efforts went ahead during 2020.
- Plans for Anaphylaxis Awareness Week changed from a fundraising initiative to *awareness raising* due to the distractions and complications of the pandemic. Despite the challenges faced by many fundraisers, over 100 people were involved in Anaphylaxis Awareness Week and an additional 75 participated in a virtual bake-off challenge. Over £7,000 was raised against a revised projected income target of £3,000.
- A significant, and unexpected, legacy of £102,965 was received in 2020 from the estate of Miss Penelope Sibson. The Will gave power of disbursement to two executors; one was Miss Sibson's goddaughter, whose son has a severe allergy to peanut, and wished for the Anaphylaxis Campaign to benefit from the estate in recognition of our advice.

Company Information

Anaphylaxis Campaign (incorporating the Latex Allergy Support Group) (the 'Campaign') was incorporated under the Companies Act on 29 December 2000 and is a company limited by guarantee. The Campaign was registered as a charity on 13 March 2001 and its governing document is a Memorandum of Association dated 29 December 2000. The Campaign is also recognised by HM Revenue & Customs as a charity for tax purposes.

The objectives of the Campaign are:

- 1. To advance the education and general understanding of the public concerning life-threatening allergies and associated disorders*
- 2. To protect the health of people who are at risk of severe allergic reactions by providing help and information to them, their families and friends.*
- 3. To promote research into the cause and care of severe allergic conditions and to publish the results of such research.*

How the Campaign's objectives benefit the public.

Severe allergic conditions, whether in a young child, teenager or adult, can have a devastating effect on everyday life, not just for those at risk, but also for their families. Our aim is to:

- raise allergy awareness for the benefit of all.
- help to protect the public by campaigning for improvements in food labelling.
- provide information of the highest quality via our helpline for allergy advice and information, our website and allergy courses, all of which are available to the general public.
- create a safer early years and school environment for all severely allergic children.
- increase the depth of knowledge that the food industry has with regard to allergy management.
- assist clinicians and other healthcare providers to have a greater understanding of severe allergy and anaphylaxis through our training programmes.
- support research into severe allergy and make the results available to the general public.

The Trustees have referred to the guidance contained in the Charity Commission's guidance on public benefit when reviewing our 3-year Strategic Plan, which set out our activities for the period 2019 – 2021 to meet our objectives.

Objective 1. To advance the education and general understanding of the public concerning life-threatening allergies and associated disorders.

What we said we would do: be the principal trusted source of information about anaphylaxis in the UK

a: through building and maintaining our reputation as a provider of quality information

b: through our training programmes

c: through our web site and social media

d: for the food industry

e: for clinicians

What we did in 2020:

a. through building and maintaining our reputation as a provider of quality information.

- Our materials continue to be produced to a strict standard, being based on high quality evidence and reviewed by clinical experts and by volunteers of the Campaign.
- We revised and republished 3 knowledgebase articles and 5 factsheets with input from our Clinical and Scientific panel.
- We developed and published the Infant Weaning Guidance and promoted this at an Infant Weaning Conference in October 2020.
- We developed a Covid 19 hub which featured the latest information on Covid 19 vaccines and allergies from the Medicines and Healthcare Products Regulatory Agency (MHRA) and The Green Book. We partnered with Allergy UK and the British Society for Allergy and Clinical Immunology (BSACI) to develop 'Frequently Asked Questions'.
- The following webinars were held during 2020 and viewed by 2,670 people:
 - Isabel Skypala 'When Allergy & Nutrition Collide': 'Rise of Reactions to Plant Foods'
 - Professor George Du Toit 'Managing your allergies in the time of Coronavirus'
 - Moira Howie, Nutrition Advisor – 'Managing your allergies in the New Reality'
 - Peter Littleton, Christeys Food Hygiene Ltd – 'The Role of Cleaning in the Management of Allergens'
 - Helen Arrowsmith, Food Law Adviser, 'Allergen information for prepacked direct sale food'
 - Richard Fielder, Bio Check 'Food Allergen Testing, has it got more complicated?'
 - Tracey Dunn, our Education Ambassador and a Headteacher – 'Making schools safer'
- Media coverage took place where the Campaign was featured or quoted on allergy issues in the following:
 - inews: Nut free Restaurant Chain- provided stats/information for a news piece.
 - BBC News: featured on BBC News online, a story on the Emerade AAI recall.
 - New Food Magazine - third podcast: featured discussing the pandemic and how it affected people with allergies and dietary requirements.
 - The Mirror: 'toxic takeaways' we appeared in a story about how an increase in takeaway culture is having an impact on allergic reactions.
 - Sunday Post: covered our Anaphylaxis Awareness Week.
- Our volunteer-led Support Group network of 23 regular groups and many more operating on a more adhoc basis continue to be supported by our Outreach Coordinator. Group Meetings are actively supported by local clinicians who specialise in allergies. Through the pandemic in 2020, Support Groups have been held virtually via Zoom. Our "Allergy Buddy" volunteers support people on a one-to-one basis, by telephone or email. This scheme has become increasingly popular with people who want to offer support, but do not have time to coordinate groups. We currently have 14 allergy buddies across the country.

b. through our training programmes

- Our AllergyWise suite of online training courses cover the vital basic information about signs and symptoms of severe allergy and anaphylaxis, emergency treatment, allergen avoidance and longer-term management of severe allergy.
- 46,500 people completed our AllergyWise courses in 2020 up 185% from 2019.
- AllergyWise for Healthcare Professionals, our "Train the Trainers" course, was re-accredited by the Royal College of Nursing and continues to be taken up by school and community nurses, first aid trainers and others who have responsibility for caring for people with severe allergies.

c. engagement achieved through our website, courses and social media platforms

- Visitors to our website grew by over 6% to 684,800 people in 2020. The number of those looking to take our AllergyWise e learning courses grew by 122% to over 70,000 people.
- Our social media following increased by 5.7% on Facebook, 43% on Twitter, 41% on LinkedIn and 35% on Instagram and our YouTube videos were viewed over 28,000 times.
- Our most viewed page on the website was the Covid Vaccine hub with over 1 million page views. Our most viewed patient information resource was the Legumes and Pulses knowledgebase resource with over 50,000 page views.

d. for the food industry

- The Corporate Panel met three times in 2020 providing guidance and expertise across the retail and service sectors where it impacted on allergic consumers.
- Bi-monthly e-newsletters for our corporate members maintained a steady flow of updates on relevant research on food allergens, testing methods, and regulatory changes. On average our corporate newsletter was dispatched to over 400 contacts and had an open rate of 20%.
- We responded through our Helpline to hot topics from industry, particularly the food sector, due to the planned changes to the regulations on labelling regarding pre-packed for direct sale foods coming into effect in October 2021. We also answered queries from food companies concerning technical issues on ingredients. Caterers expressed particular concerns about providing accurate information for food allergic customers.
- Our Covid 19 hub has information for food business who were affected in a variety of different ways and have had to adapt their business models to frequently changing rules and regulations. We provide information to help them comply with relevant allergen and hygiene regulations.
- We participated in the consultation process for the update to the 'Food Allergen Labelling and Information: Technical Guidance' for the upcoming changes for pre-packed for direct sale foods (Natasha's law) coming into effect in October 2021. The updated guidance was published in 2020.
- Our CEO spoke at a number of conferences and training events including Dunbia Food Safety Week, The Society of Food Hygiene and Technology conference and ADM Protexin Training Day, as well as several online events.

e. for clinicians

- We provided accredited training through our online AllergyWise programme to over 300 GPs, practice nurses, school nurses and other healthcare professionals. We continued to signpost our AllergyWise courses, and our patient and healthcare information to allergy clinics.
- We sent bi-monthly newsletters to our healthcare members which signposted to our patient materials and AllergyWise training courses. They also featured many articles including information on immunotherapy, the latest news on Covid 19 vaccination and allergies, NICE guidance, the latest allergy hospital admissions data from the NHS and updates on the current situation with regards to adrenaline auto-injectors. These bi-monthly newsletters had an average open rate of 41%.
- We developed a comprehensive webinar programme for healthcare professionals which included webinars by Isabel Skypala – talking about when 'Nutrition and Allergy Collide' and Dr Helen Howells on Prescribing Adrenaline Auto Injectors.

-
- The Clinical and Scientific Panel was relaunched with Professor John Warner as its new chair in the summer of 2020, bringing together allergy expertise from across the country to inform the work of the Anaphylaxis Campaign.
 - We actively engaged in work with clinical partners to develop research to look at how ethnicity issues impact on those affected by severe allergies.

Objective 2. To protect the health of people at risk of severe allergic reactions by providing help and information to them, their families and friends.

What we said we would do: Campaign on behalf of people at risk of severe allergic reactions

What we did in 2020:

- **We worked with other key agencies to effect improvements in services for severely allergic people nationally and internationally.** During the year, the Campaign continued to be involved at the highest level with government, medical and voluntary organisations, such as the Food Standards Agency, British Society for Allergy and Immunology and European Academy of Allergy and Immunology.
- We continue to work closely with bereaved families and to consider the information in Coroners reports.

As part of our Universities and Adults project:

- We worked in partnership in the University Catering organisation (TUCO) to support young people with allergies through the Covid 19 pandemic with the publication of an article on the TUCO website. With our Youth Ambassador we developed a Q&A podcast to reach out to young people at home and university which has been viewed 222 times.

As part of our Making Schools Safer Project:

- Tracey Dunn gave a webinar entitled 'Making Schools Safer - Allergies and Covid 19' which was oversubscribed and then repeated 10 days later. We collaborated with one of our volunteers to update our key stage 1 and 2 resources for schools.
- Our CEO made a film with ITN for the BSACI conference in October 2020 talking about AllergyWise, spare pens in schools and carrying two adrenaline auto Injectors.

As part of our Food Services Project:

We used our database of Local Authorities and Trading Standards to share best practice and learnings from coroner inquests in two mailings opened by 136 local authorities.

- We worked in partnership with the Food Standards Agency to consult on the updated technical guidance issued in advance of the introduction of 'Natasha's Law' in October 2021.
- We worked with Codex Alimentarius, the organisation that develops international food trade standards, to represent the voice of the allergic consumer on their work to revise the allergen provisions of the General Standard for labelling of pre-packaged foods.
- Following the COVID-19 outbreak, we provided detailed information and links for food businesses, who had to rapidly adapt, on our website COVID-19 pages.

As part of our Primary Care Project:

- We developed a toolkit for Primary Care providing clinically based information on diagnosis, treatments, prescribing and resources. We have mailed these to Clinical Commissioning Groups, Local Medical Committees and healthcare professional members to support the provision of outstanding care to allergy patients. Working with the Pharmacy Defence Association we reached over 2,900 healthcare professionals with these resources.
- We produced a toolkit for pharmacists to help support patients who have a severe allergic reaction to their vaccinations and also ensure patients carrying adrenaline auto-injectors (AAIs) for severe allergies are trained in how to use them correctly. This was sent to over 30,000 pharmacists.

Objective 3. To promote research into the cause and care of severe allergic conditions and to publish the results of such research.

What we said we would do: support and fund research that improves services and quality of life for patients: What we did in 2020:

Facilitated many research projects – the Campaign assisted the following organisations with research projects into severe allergies during 2020:

- Worked in partnership with DBV on their Qualitative Evaluation of Health-related Quality of Life Associated with Peanut Allergy: Patient and Carer Vignette and Burden of Illness Study.
- Working in partnership with Aimmune to support the dissemination of the Peanut Allergy/Quality of Life survey.
- Working in partnership with Aimmune to recruit families for a study regarding allergy Disease Awareness/Media Work.
- Working with the Food Standards agency to recruit families for a cost of living with allergy study.

Structure, Governance and Management

The Campaign's Memorandum of Association sets out the objects and powers of the charitable company and is governed under its Articles of Association. Under those Articles, the Trustees are elected at the Annual General Meeting to serve for a period of approximately three years.

Trustees are recruited to ensure a balanced board with a mix of skills. All new Trustees are given an induction which includes learning about the background, ethos and day to day activities of the Campaign as well as outlining their responsibilities. The maximum number of Trustees allowed by the Campaign's governing document is eleven and at 31 December 2020 there were nine. Trustees may be co-opted by the board as considered necessary and those co-opted may serve until the Annual General Meeting following their co-option, at which time they must stand for election if they wish to remain on the Board.

The Governance structure is made up of a Board of Trustees. The Chief Executive is not a Trustee but a permanent non-voting member of the Board, with the right to attend all Board meetings unless a conflict of interest exists. The Business Manager for the Campaign is also its Company Secretary. Other members of staff from the Campaign attend as required.

The Board usually meets quarterly and holds an annual Strategy Day in addition, which all Trustees and the Chief Executive are expected to attend. Trustees may also attend any of the Campaign's conferences and events relevant to their particular roles during the year. From the beginning of April 2020 to December 2020 Board meetings were held monthly via Zoom.

The Campaign operates in a consistent way by following the policies set out and agreed by the Board, supported and implemented by the Chief Executive, Mrs. Lynne Regent and her staff. Day to day responsibility rests with the Chief Executive, who is responsible for all staff.

Strategy 2019-2021

The key objectives for 2019-2021 were set out in the Business Plan 2019 agreed by the Board in March 2019. The key priorities for the Campaign were agreed as follows;

- Improve safety and quality of life for people affected by anaphylaxis
- Grow the reach of the Campaign increasing profile and awareness of our work
- Help achieve wider NHS availability of oral immunotherapy to key allergens in partnership with pharmaceuticals (ALK, Aimmune, DBV).
- Engage with Government on critical allergy related initiatives. Develop strong relationships with key Ministers, Parliamentary groups, focussing on Health, Education and Industry
- Generic AAls to be available in most schools and address key issues in adrenaline provision
- Increase uptake of AllergyWise training programmes in schools
- Working with universities to develop education resources appropriate for this target group (especially Freshers)
- Help food industry and services become safer through better labelling and information with improved application of regulatory standards and controls.
- Help achieve fewer anaphylaxis fatalities and support those bereaved by anaphylaxis in an effective way.
- Aim to get to an active support group meeting in each county.

The Business plan has been monitored by the Board at each of their meetings. The performance objectives of each member of staff directly relate to the Business Plan and the overall strategic direction.

From April 2020 all staff worked virtually from home with full electronic, but secure access to central files. With technical support the Helpline and Information Team provided a full service as demand for our advice increased markedly in 2021. Our CEO held weekly virtual meetings with all staff participating via a sound and visual link as well as one to one meetings. A member of staff visited our office on a weekly basis to process incoming post. During this period all staff received diversity training.

Investment performance achieved against investment objectives

The investment objectives of the Campaign are to maximise the value of reserves, while avoiding undue risk. The Campaign's policy on investment includes a requirement to limit investments to 60% of liquid assets and only to invest in Funds regulated by the Financial Conduct Authority. The Campaign's investments in an Income and Growth portfolio with Hargreaves Lansdown showed a loss of £6,941 on the value report at the end of December 2019 (£163,091). The value at the end of December 2020 was £156,150.

Financial review Reserves policy

To achieve a sound balance between prudence and ensuring funds are expended in achieving the objectives of the Campaign, the Trustees have established a policy whereby the unrestricted reserves held by the Campaign should equate to at least six months operating cost. At the year end this equated to £252,384. Free reserves (excluding 6 months operating costs) at 31 December 2020 stood at £300,954.

Restricted reserves

Details of restricted funds are shown in note 16 of the financial statements.

Risk review

The Trustees have conducted a review of the major risks to which the Campaign is exposed and systems have been established to manage those risks. A risk management register is maintained and risks highlighted are reviewed regularly to ensure they do not pose a threat to the Campaign going forward. Key risks for the Campaign include potential for loss of expertise and/or revenue from donations and fundraising activities. All Trustees received regular governance training.

Financial overview

The Campaign ended the year in a sound financial position with £7,496 already in hand to fund projects in 2021 and sufficient free reserves to meet its reserves policy. Net outgoing resources for the year amounted to £495,062. Unrestricted funds were £553,338 and restricted funds £7,496. COVID has had a significant impact on the operations of the Anaphylaxis Campaign, including the need to change employment contracts to deal with furlough. Detailed consideration is being given to further changes to the organisation that might be implemented. As a consequence, legal fees have been considerably higher in the year under review.

Financial policies

All payments up to £10,000 made by the Campaign have to be signed by two authorised signatories and by a Trustee in addition for payments over that amount. The day-to-day management of the financial affairs of the Campaign is delegated to the Business Manager who submits Management Accounts and a written report monthly to the CEO and Board of Trustees. A financial report supported by Management Accounts is delivered at each meeting of Trustees.

Principal funding sources

The principal funding sources for the Campaign are donations from a variety of individuals and Gift Aid and membership subscriptions. The Campaign seeks funds from companies, charitable trusts and other sources to fund running costs and specific projects.

We are particularly grateful for grants from the Barbara Ward Children's Foundation and the Garfield Weston Foundation.

Uses of funds

The funds received by the Campaign during the year have helped to finance our Helpline and Information services, Support Group development, Adult Allergy campaigns, outreach to young people with severe allergies, research programmes, and our training for health professionals.

Plans for the future

The Board have agreed a Strategic Framework for 2019-2021. The general impact the Anaphylaxis Campaign aims to achieve by the end of 2021 is:

- Improved safety and quality of life for people affected by anaphylaxis including clinical, practical and psychological aspects.
- Wider reach to more people affected by anaphylaxis and ensuring that more organisations interacting with people with anaphylaxis know about the Anaphylaxis Campaign and are supported by our information and services.
- Campaigning for society-wide positive change for those with anaphylaxis, by influencing at government level on critical issues.

Our main priority areas and the impact we aim to achieve within each area are set out in the Business Plan approved by the Board in March 2019. These priorities are reflected in the Business Plan which were approved by the Board in March 2019. The main areas for future work will be:

- **Early Years and Schools;** Help to keep children safe by providing information, training and support in early years and schools settings
- **Universities and Adults:** Help adults of all ages stay safe, with a special focus on young adults (16-24) with anaphylaxis, helping them to manage the transition of moving away to college /university/own home and employment
- **Food:** Help the food industry become safer through better labelling, and information provision, and improved application of regulatory standards, and controls.
- **Primary Care:** working with Clinical Commissioning Groups to improve the quality of prescribing and dispensing of Adrenaline Auto Injectors across Primary Care
- **Fatalities:** Share learning from anaphylaxis fatalities and support those bereaved by anaphylaxis in an effective way.

The Board will agree a new strategic direction in 2021 for 2021 to 2023. Also a consultation was held in December 2020 regarding proposed constitutional changes for the charity. It is envisaged that these changes will be implemented in 2021.

Statement of Trustees' responsibilities

The trustees (who are also directors of the Campaign for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Auditor

Chamberlains were appointed auditors at the Annual General Meeting of the Campaign held on 11th December 2019. The AGM for 2020 was deferred.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

This report was approved by the Trustees on 28 June 2021 and signed on their behalf.

Mrs. Sarah Lassman
Chair

Independent Auditor's Report to the Members of The Anaphylaxis Campaign (Incorporating the Latex Allergy Support Group)

Opinion

We have audited the financial statements of The Anaphylaxis Campaign (Incorporating the Latex Allergy Support Group) (the 'charitable company') for the year ended 31 December 2020 which comprise statement of financial activities, balance sheet and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2020, and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charitable company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the trustees' annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemptions in preparing the directors' report and from the requirement to prepare a strategic report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 11 the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Paul Chamberlain (Senior Statutory Auditor)
For and on behalf of Chamberlains Statutory Auditors and Chartered Accountants
Elm House, Tanshire Park
Shackleford Road, Elstead
Godalming, Surrey
GU8 6LB

Date: 26 July 2021

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Statement of financial activities (incorporating an income and expenditure account)

Year ended 31 December 2020

	Notes	Unrestricted funds £	Restricted Funds £	Total 2020 £	Unrestricted funds £	Restricted funds £	Total 2019 £
Income from:							
Donations	2	382,487	63,387	445,874	340,212	36,000	376,212
Other trading activities	2	77,668	-	77,668	96,664	-	96,664
Income from investments	3	1,582	-	1,582	1,998	-	1,998
Income from charitable activities	2	97,157	-	97,157	81,734	-	81,734
Total income		558,894	63,387	622,281	520,608	36,000	556,608
Expenditure on:							
Raising funds		28,188	-	28,188	27,408	-	27,408
Charitable activities		384,097	82,776	466,874	488,587	20,354	508,941
Total expenditure	4	412,285	82,776	495,062	515,995	20,354	536,349
Net (losses)/gains on investments	11	(6,941)	-	(6,941)	15,866	-	15,866
Net income/(expenditure)		139,668	(19,389)	120,279	20,479	15,646	36,125
Transfer between funds		28,756	(28,756)	-	4,533	(4,533)	-
Net movement in Funds		168,424	(48,145)	120,279	25,012	11,113	36,125
Reconciliation of funds:							
Total funds brought forward		384,914	55,641	440,555	359,902	44,528	404,430
Total funds carried forward	15 / 16	553,338	7,496	560,834	384,914	55,641	440,555

The Statement of financial activities includes all gains and losses in the year.

All income and expenditure derive from continuing activities.

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Balance Sheet

Year ended 31 December 2020

	Note	2020 £	2019 £
Fixed Assets			
Tangible assets	10	15,407	23,762
Investments	11	156,150	163,091
		<u>171,557</u>	<u>186,853</u>
Current assets			
Stock		2,193	2,548
Debtors	12	64,051	73,642
Cash at bank		357,362	222,985
		<u>423,606</u>	<u>299,175</u>
Creditors - amounts falling due within one year	13	(34,329)	(45,473)
Net current assets		389,277	253,702
Total assets less current liabilities		<u>560,834</u>	<u>440,555</u>
Funds			
Restricted funds	16	7,496	55,641
Unrestricted funds	15	553,337	384,914
Total funds		<u>560,833</u>	<u>440,555</u>

These financial statements have been prepared in accordance with the special provisions of Section 15 of the Companies Act 2006 relating to small companies.

Approved by the Trustees and authorised for issue on 16 May 2021 and signed on their behalf by:

Sarah Lassman - Trustee

Company Registration Number: 04133242

The notes on pages 17 to 28 form part of these financial statements.

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Statement of Cash Flows

Year ended 31 December 2020

	Note	2020 £	2019 £
Cash flows from operating activities	20	134,292	16,463
Cash flows from investing activities			
Purchase of fixed assets		(1,497)	(12,343)
Interest received		1,582	1,998
Net cash flow from investing activities		85	(10,345)
Net increase/(decrease) in cash and cash equivalents		134,377	6,118
Cash and cash equivalents at beginning of year		222,985	216,867
Cash and cash equivalents at end of year		357,362	222,985

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements

Year ended 31 December 2020

1. Accounting policies

General information

The Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group) is a company limited by guarantee in the United Kingdom. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The address of the registered office is given in the charity information on page 2 of these financial statements. The nature of the charity's operations and principal activities are to: a) advance the education and general understanding of the public concerning life-threatening allergies and associated disorders; b) to protect the health of people who may be at risk of severe allergic reactions by providing help and information to them, their family and friends; and c) to promote research into the cause and care of severe allergic conditions and to publish the results of such research.

The charity constitutes a public benefit entity as defined by FRS102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) issued on 16 July 2014, the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102), the Companies Act 2006 and UK Generally Accepted Practice.

Basis of preparation

The financial statements have been prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value.

The financial statements are prepared in sterling and monetary amounts are rounded to the nearest £.

The significant accounting policies applied in the preparation of these financial statements are set out below.

These policies have been consistently applied to all years presented unless otherwise stated.

Tangible Fixed Assets

All fixed assets to a value of £50 or more are capitalised at cost. Depreciation is provided on all fixed assets at rates calculated to write off the cost of the asset over its expected useful life as follows:

Equipment: 25% straight line on cost

Income recognition

All incoming resources are included in the Statement of Financial Activities (SoFA) when the charity is legally entitled to the income after performance conditions have been met, the amount can be measured reliably and it is probable that the income will be received.

Donations and subscriptions

Membership donations, memorial donations, major donors, legacies and charitable trust income is recognised on a receipts basis.

Corporate donations, corporate membership and professional membership income is recognised on a receivable basis.

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2020

1. Accounting policies (continued)

Income recognition (continued)

Donations and subscriptions (continued)

Individual membership received by direct debit is recognised on a receivable basis. For those members who pay by cheque or credit card, recognition is on a received basis.

Gift Aid income includes the Gift Aid on all applicable donations received in the year under review.

Gifts in kind

Donated professional services are recognised in income at their fair value when their economic benefit is probable, it can be measured reliably and the Campaign has control over the item. Fair value is determined on the basis of the value of the gift to the charity. For example the amount the charity would be willing to pay in the open market for such services. A corresponding amount is recognised in expenditure.

Community fundraising

Income is recognised on a received basis.

Event income and corporate sponsorship

Income earned from fundraising and sponsored events is recognised on the date the event is held.

Sale of educational products

Income is received for the sale of online "AllergyWise" courses written by the Campaign. Income is recognised on a received basis.

Product recall income

Product recall income is income received from retailers for the Campaign, contacting their members about mislabelled products. The invoiced amount is based on the type of product mislabelled, the difference types of alerts sent and the membership status of the retailer. Income is recognised on a receivable basis net of VAT.

Investment income

Investment income is earned through holding assets for investment purposes, and includes dividends and interest. Where it is not practicable to identify investment management costs incurred within a scheme with reasonable accuracy the investment income is reported net of these costs. It is included when the amount can be measured reliably. Investment income is recognised on a received basis.

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2020

1. Accounting policies (continued)

Expenditure

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate

Costs of raising funds: includes all direct fundraising costs, including costs of staff specifically engaged in community, trust and corporate fundraising.

Costs of charitable activities: includes all costs (including support costs) for the Campaign's activities in meeting our charitable objectives.

Governance costs: includes costs incurred in the governance of the charity and its assets, primarily associated with constitutional and statutory requirements.

Support costs allocation

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office expenses, governance costs, administrative payroll costs. They are incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters. Where support costs cannot be directly attributable to particular headings they have been allocated to cost of raising funds and expenditure on charitable activities on a basis consistent with use of the resources. Premises and other overheads have been allocated on an accruals basis.

Fund-raising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities.

The analysis of these costs is included in note 5.

Debtors

Trade and other debtors are recognised at the settlement amount due after any discounts offered to members. Prepayments are valued at the amount prepaid.

Cash at bank

Cash at bank includes cash and fixed term deposit accounts with a short term maturity of twelve months.

Creditors and provisions

Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any discounts due.

Fund accounting

Unrestricted funds are available to spend on activities that further any of the purposes of the Campaign. Designated funds are unrestricted funds of the charity which the Trustees have decided at their discretion to set aside to use for a specific purpose. Restricted funds are donations which the donor has specified are to be solely used for particular areas of the Campaign's work or for specific projects being undertaken by the Campaign.

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2020

1. Accounting policies (continued)

Leasing

Rentals payable under operating leases are charged against income on a straight line basis over the lease term.

Taxation

The charitable company's activities are exempt from taxation under Sections 466-493 of the Corporation Tax Act 2010.

Investments

The carrying value of the investment at the accounting date represents the fair value of the underlying quoted investments and deposits.

The net realised and unrealised gains and losses of the underlying investments are reflected through the statement of financial activities.

Pensions

The charity operates a defined contribution plan for the benefit of its employees. Contributions are expensed as they become payable.

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2020

2. Incoming resources

Donations	2020	2019
	£	£
Membership donations	30,595	31,669
Memoriam donations	7,340	34,645
Corporate donations	4,414	15,407
Charitable trust income & major donors	56,550	39,300
Legacies	103,965	2,000
Gift aid	18,814	21,290
Community fundraising	42,734	84,831
Individual membership	55,701	59,521
Professional membership	6,252	6,281
Corporate memberships	64,115	68,260
Other - including COVID support funding	55,393	13,008
	445,873	376,212

Included in legacies are amounts of £102,965 from the estate of Penelope Sibson and £1,000 from the estate of Wendy Thomson.

Other trading activities	2020	2019
	£	£
Sale of goods	4,668	5,681
Advertising	720	970
Event income	-	25,791
Corporate sponsorship	-	16,250
Special project income	63,687	37,369
Other	8,593	10,603
	77,668	96,664

Charitable activities	2020	2019
	£	£
Sale of education products	36,932	25,223
Product recall income	60,225	56,511
	97,157	81,734

3. Income from investments	2020	2019
	£	£
Bank Interest	1,582	1,998

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2020

4. Total expenditure	Activities undertaken directly £	Support costs £	Total 2020 £	Total 2019 £
Raising funds	28,188	-	28,188	27,408
Charitable activities	219,243	221,317	440,560	485,821
Governance costs	-	26,314	26,314	23,121
Total	247,431	247,631	495,062	536,350

5. Allocation of support costs

	Basis of apportionment	Support costs £	Total 2020 £	Total 2019 £
Staff costs	Staff time	92,246	92,246	82,930
Office rental and other office costs	Invoiced events	70,853	70,853	74,467
Travel expenses	Non-governance expenses	1,554	1,554	9,644
Legal / Professional costs	Invoiced events	26,706	26,706	3,790
Finance expenses	Bank charges payable	5,195	5,195	4,727
Website costs	Software cost and usage	5,617	5,617	7,072
Depreciation	Estimated useful life	9,852	9,852	13,327
Other costs	Invoiced events	9,294	9,294	13,245
		221,317	221,317	209,202

6. Allocation of governance costs

	Activities undertaken directly £	Total 2020 £	Total 2019 £
Staff costs	19,086	19,086	15,143
Audit fees	5,750	5,750	6,500
Travel and subsistence expenses	1,478	1,478	1,478
	26,314	26,314	23,121

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2020

7. Staff

The average monthly number of employees and full time equivalent (FTE) during the year was as follows:

	2020 Number	2020 FTE	2019 Number	2019 FTE
Raising funds	3	2	3	2
Charitable activities	10	8	10	8
Governance	-	-	-	-
	<u>13</u>	<u>10</u>	<u>13</u>	<u>10</u>

The total staff costs and employees benefits was as follows:

	2020 £	2019 £
Staff costs		
Wages & salaries	277,830	295,303
Employers NI	17,208	19,380
Pension costs	4,865	5,122
	<u>299,903</u>	<u>319,805</u>

None of the Trustees was employed by the Campaign, or had any interest in any contracts with the Campaign in either year. During the year £302 in respect of travel was reimbursed to two Trustees for expenditure incurred on the Campaign's business (2019: £1,189 - three Trustees).

No employee was paid more than £60,000 in either 2020 or 2019.

The key management personnel of The Campaign is the Chief Executive Officer, whose employee benefits total £53,796 (2019: £52,162).

8. Net income / (expenditure) for the year

The net income / (expenditure) is stated after charging / (crediting):	2020 £	2019 £
Depreciation of tangible fixed assets	9,852	13,327
Operating lease rentals	<u>29,000</u>	<u>29,000</u>

9. Auditor's remuneration

The auditor's remuneration amounts to an audit fee of £5,000 (2019: £5,000)

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2020

10. Fixed assets

Cost	Equipment
	£
At 1 January 2020	122,498
Additions	1,497
Disposals	(37,877)
At 31 December 2020	<u>86,118</u>
Depreciation	
At 1 January 2020	98,736
Charge for the year	9,852
Disposals	(37,877)
At 31 December 2020	<u>70,711</u>
Net book value	
At 31 December 2020	<u>15,407</u>
At 31 December 2019	<u>23,762</u>

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2020

11. Investments

	2020	2019
	£	£
Market value at 1 January	163,091	147,225
Additions	-	-
Disposals	-	-
Unrealised (loss)/gain on revaluation	(6,941)	15,866
Market value at 31 December	<u>156,150</u>	<u>163,091</u>

	2020		2019	
	Market value	Cost	Market value	Cost
	£	£	£	£
Quoted investments				
UK - equities	155,115	132,963	161,479	132,963
Cash fund	1,035	1,035	1,612	1,612
	<u>156,150</u>	<u>133,998</u>	<u>163,091</u>	<u>134,575</u>

Included in the market value of investments at 31 December 2020 individual investments that are material to the investment portfolio valuation were:

	No. of ordinary shares / units	Market value	Cost at 31 December 2020	Percentage of total valuation
HL Multi-Manager Income & Growth Trust	73,493	£ 63,513	£ 56,392	40.7%
HL Multi-Manager Strategic Bond Trust	40,872	£ 63,629	£ 52,364	40.7%
HL Multi-High Income Trust	15,731	£ 15,960	£ 16,193	10.2%

The income shown above is after management fees.

12. Debtors

	2020	2019
	£	£
Trade debtors	18,279	29,630
Prepayments	38,934	32,604
Accrued income	4,758	5,040
HMRC VAT liability (repayment)	2,080	6,368
	<u>64,051</u>	<u>73,642</u>

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2020

13. Creditors	2020	2019
	£	£
Trade creditors	3,723	22,358
Other taxation and social security	5,283	6,908
Accruals	8,691	7,327
Deferred income (see note 14)	16,632	8,880
	<u>34,329</u>	<u>45,473</u>
14. Deferred income	2020	2019
	£	£
Income received in advance	<u>16,632</u>	<u>8,880</u>
	2020	2019
	£	£
At 1 January 2019	8,880	5,670
Amount released to incoming resources	(8,880)	(5,670)
Amount deferred in the year	16,632	8,880
As at 31 December 2019	<u>16,632</u>	<u>8,880</u>
Income in support of 2021 activities was the following:		
Corporate Subscriptions	8,880	8,880
	<u>8,880</u>	<u>8,880</u>

Income has been deferred for the above sponsorship, donations and subscriptions as they relate to events which are due to take place in 2021.

15. Unrestricted funds

	At 1 January 2020	Incoming resources	Outgoing resources	Gain on investment	Transfer to/from unrestricted	At 31 December 2020
	£	£	£	£	£	£
General fund	384,914	558,894	(412,285)	(6,941)	28,756	553,338
	<u>384,914</u>	<u>558,894</u>	<u>(412,285)</u>	<u>(6,941)</u>	<u>28,756</u>	<u>553,338</u>

Name of unrestricted fund

General fund

Description, nature and purpose of the fund

The 'free reserves' after allowing for all designated funds.

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Notes to the financial statements (continued)

Year ended 31 December 2020

16. Restricted funds

	At 1 January 2020 £	Incoming resources £	Outgoing resources £	Transfer to/from unrestricted £	At 31 December 2020 £
Isle of Man Fund	6,293				6,293
Support for Adults	8,199		(8,199)		-
Support for Pharmacies	12,393		(12,393)		-
Mylan Spare Pens	28,756			(28,756)	-
Support for Primary Care		10,000	(10,000)		-
Campaign for CCGs		4,500	(4,500)		-
Webinar for General Practice		1,500	(1,500)		-
DBV/Bresmed Project		232	(232)		-
Making Schools Safer Project		14,000	(14,000)		-
Back to School Campaign		22,500	(22,500)		-
Review of Educational Material		780	(780)		-
Switch Campaign		1,750	(1,750)		-
Mylan Speed Campaign		2,252	(2,252)		-
FSA Research Project		4,000	(3,700)		300
Survey, Review and Report		1,873	(970)		903
	55,641	63,387	(82,776)	(28,756)	7,496

17. Analysis of net assets between funds

	Unrestricted £	Restricted £	Total 2020 1	Total 2019 £
Fixed tangible assets	15,407	-	15,407	23,762
Fixed investment	156,150	-	156,150	163,091
Current assets	416,110	7,496	423,606	299,175
Current liabilities	(34,329)	-	(34,329)	(45,473)
	553,338	7,496	560,834	440,555

18. Operating leases

Future minimum payments under non-cancellable operating leases are £36,250 (2019: £65,250).

19. Pensions

The charity operates a defined contribution pension plan for its employees. The amount recognised as an expense in the year was £4,865 (2019: £5,122) included within unrestricted charitable activities and support costs.

20. Reconciliation of Net Movement in Funds to Net Cash Flow from Operating Activities

	2020 £	2019 £
Net movement in funds	120,279	36,125
Add back depreciation	9,852	13,327
(Deduct)/add back (gains)/losses on investments	6,941	(15,866)
(Deduct) interest income	(1,582)	(1,998)
(Increase)/decrease in stock	355	(677)
(Increase)/decrease in debtors	9,591	(28,856)
Increase/(decrease) in creditors	(11,144)	14,408
Net cash generated in operating activities	134,292	16,463

Anaphylaxis Campaign (Incorporating The Latex Allergy Support Group)

Detailed income and expenditure account

Year ended 31 December 2020

	2020		2019	
	£	£	£	£
Income				
Subscriptions		126,068		134,062
Donations - members		30,595		31,669
Donations - other		246,477		125,650
Product Alerts income		60,225		56,511
Advertising & Sponsorship		720		17,220
Sale Proceeds		41,600		30,904
Community fundraising & events		42,734		110,622
Special project income		63,687		37,369
Other sundry income		8,593		10,603
Bank interest		1,582		1,998
		<u>622,281</u>		<u>556,608</u>
Cost of sales (net of closing stock value)		<u>(2,798)</u>		<u>(3,489)</u>
		619,483		553,119
Expenditure				
Wages & salaries	299,903		319,805	
Subcontract consultants	27,141		24,526	
Communications, magazine, design	5,198		7,961	
Website	5,617		7,072	
Fundraising expenses	6,335		10,279	
Conferences & events	1,650		20,955	
Office expenses	1,881		3,134	
Rent & rates	31,541		31,454	
Light & heat	1,342		4,173	
Staff training	(84)		2,991	
Staff recruitment	-		10,335	
Telephone & internet	4,355		4,550	
Stationery & printing	1,117		1,779	
Postage & carriage	3,973		5,329	
Photocopying	320		1,055	
Travel, subsistence & accommodation	3,032		11,122	
Computer and software	23,917		20,752	
Insurance	2,407		2,241	
Bank charges	5,195		4,727	
Audit	5,750		6,500	
Professional fees	26,706		3,790	
Depreciation	9,852		13,327	
Subscriptions & journals	770		748	
Sundry	487		1,162	
Irrecoverable VAT	8,037		11,335	
Bad debts	-		-	
Special Projects & research grants	15,731		1,122	
Support Groups	90		636	
		<u>(492,263)</u>		<u>(532,860)</u>
Surplus for the year from operations		127,220		20,259
Gain/loss on investments		<u>(6,941)</u>		<u>15,866</u>
Total surplus for the year		<u>120,279</u>		<u>36,125</u>